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Human papillomavirus (HPV) is the world’s most common sexually transmitted 
infection and its consequence cervical cancer is one of the world’s most common 
cancer forms. Revolutionary advances in HPV testing and HPV vaccination have the 
potential to radically change women’s health. However, several challenges remain 
before effective cervical cancer control can be reached.  
 
This thesis has exploited the excellent Swedish register and biobank 
infrastructure, for studies aiming to inform HPV-based prevention of cervical cancer. 
To this end, we have combined epidemiological, virological and biostatistical 
investigation of the use of HPV-tests in organized cervical screening. We also 
investigated awareness of HPV and acceptability of HPV vaccination in the population. 
Study I was a molecular epidemiological case-control study, nested within the 
Swedish cervical screening program, including 515 women with cancer in situ (CIS), 
315 women with invasive squamous cervical cancer (SCC), and matched control 
women. 2772 archival cervical smears were gathered and subjected to full HPV-typing. 
The median follow-up was 5-7 years. We provide prospective evidence that infection 
with non-16/18 high-risk HPV types, and persistent infection with HPV16, both confer 
increased risks for future invasive cervical cancer. 
In Study II, we extended this case-control study to include 621 women with CIS 
and 457 women with SCC; a uniquely large sample. Here, 5665 archival smears were 
tested for HPV, and HPV16 positive smears further analyzed for HPV16 viral load 
through realtime-PCR. The median follow-up was 6-8 years. We show that HPV16 
viral load predicts risk for both CIS and SCC, but also that the risk functions differ per 
diagnosis and over time. Thus, HPV16 viral load appears highly complex which may 
limit its use in HPV-based cervical screening. We further show unexpectedly low viral 
loads early in invasive disease, which may carry implications for the weighing of 
sensitivity against specificity in HPV testing. 
In Study III, we report results from a cross-sectional population-based survey 
examining awareness and knowledge of HPV in 24,513 adult Swedish respondents. We 
show that awareness of condyloma and cervical cancer was high, but that awareness 
and understanding of their causal factor HPV was poor. The knowledge that men could 
contract HPV needs to be improved. Education campaigns on HPV should particularly 
target young men, and those of low education. 
Finally, Study IV was also a cross-sectional survey, examining acceptability of 
HPV vaccination among 10,567 young adults age 18-30 in Sweden. We show that 
willingness to vaccinate was quite high, but that information on the benefits of 
vaccinating before sexual debut is important. Few adults stated their health-care related 
behavior would change after vaccination, but a number were uncertain, suggesting an 
educational need when vaccinating this group. A perceived risk of side effects was the 
largest potential barrier to vaccination. 
 
Our findings should assist risk stratification in HPV-based screening, and design of 
HPV vaccination campaigns. Future research should include investigations of cervical 
screening attendance, HPV vaccine uptake and acceptability of HPV-based screening. 
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1 INTRODUCTION 
 
Human papillomavirus (HPV) is the world’s most common sexually transmitted 
infection (STI) and causes significant morbidity and mortality. Yet, it is probably the 
STI of which, until recently, the least had been spoken. One of its chief consequences is 
invasive cervical cancer: one of the most common cancers in the world and which, if 
unscreened for, frequently strikes women of a young age.  
 
Since the introduction of a national organized cervical screening program, incidence 
and mortality in cervical cancer have been considerably reduced in Sweden. The 
evidence-based rationale for such screening is therefore very strong. However, the 
incidence of squamous cell carcinoma is no longer decreasing and adenocarcinoma of 
the cervix is increasing.  
 
Fortunately, and perhaps at the turn of the tide, promising new HPV-based prevention 
methods have emerged. Ensuring the proper evaluation of, and equal access to, these 
new prevention methods should be an important ethical priority for public health 
research. If the full potential of these methods is realized, it might be achievable to 
reach the final, visionary goal: the eradication of cervical cancer. 
 
It has been the goal of this thesis to exploit the excellent Swedish register and biobank 
infrastructure for studies aiming to advance the prevention of cervical cancer. To this 
end, it has combined epidemiological, virological and biostatistical investigation of       
i) the use of HPV tests and HPV viral load in organized cervical screening and            
ii) awareness of HPV and acceptability of vaccination against HPV. The work 
presented here therefore encompasses several aspects of cervical cancer causation and 
prevention; from the significance of viral etiology and molecular markers to societal 






2.1 HUMAN PAPILLOMAVIRUS INFECTION 
Papillomaviruses are a diverse family of viruses found in most mammals and birds, 
capable of causing epithelial tumors in humans and some related species. The name 
derives from the Latin word Pailla - a nipple-like projection and the Greek word oma - 
a swelling or tumor. The types found in humans are termed human papillomavirus 
(HPV) and constitute a large family in the human host; over 100 HPV types have been 
identified, of which 40 infect the genital tract. Many of these types have been shown to 
be ubiquitously distributed around the globe (1), and some appear to have become more 
common in the population (2, 3). 
  
HPV transmission occurs primarily during sexual activity, and as such HPV infection is 
the world’s most common sexually transmitted infection (STI). The prevalence in 
women is most common before age 30, but there is a second incidence peak later on in 
life. In men, however, the prevalence is more stable across all ages (4). Most infections 
are asymptomatic with most women (75-80%) infected with HPV at some time during 
their life, but longitudinal studies show that 90% of infections are cleared within one-
two years (5). It is unclear whether HPV is sufficiently infectious to be transmissible 
during the entire duration of the infection(6). Oral HPV is mainly transmitted through 
oral sex or open-mouth kissing (7), whereas genital HPV is transmitted through skin-to-
skin contact during sexual activity, and not the exchange of body fluids like in other 
(bacterial) STI’s such as Chlamydia and gonorrhea. This means that protection 
conferred by condoms exists, but is not complete (8). Other transmission routes known 
for HPV include vertical transmission from mother to infant, a risk which is greater 
after vaginal than caesarean birth (9). 
 
HPV has a particular affinity to so-called squamocolumnar junctions, where there is a 
transition between squamous and glandular cells in an epithelium. Such junctions are 
found in the cervix, anus and tonsils and HPV is also capable of residing on skin tissue, 
e.g. on the penis (5). In addition to this, HPV infections appear capable of site-to-site 
transmission (or auto-inoculation), meaning that a woman who is cervicovaginally 
positive may well become anally positive for the same type within a certain time 
interval (4), and indeed, anal HPV infections are common in young women (10).  
 
HPV types are traditionally divided into low-oncogenic-risk types and high-oncogenic-
risk types – which will below be referred to as low-risk (LR-HPV), and high-risk (HR-
HPV), respectively. This since the different types exhibit different disease-causing 
characteristics. The most noted low-risk types, where cancer risk is negligible (11), are 
HPV6 and HPV11, responsible for 90 percent of genital warts, and causative of the rare 
disease recurrent respiratory papillomatosis (RRP) (12). Around 13-15 HR-HPV types 
have been identified, the most noted of which are HPV16 and HPV18, together held 
accountable for 70% of cervical cancer tumor cases and are as such the primary targets 
for globally intended vaccines (see further below). HPV16, which has been described 
as “the major player” (13), occupies a particularly important place in the HPV-related 
disease pantheon due to its strong carcinogenicity. 
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Apart from viral genotype, it is now understood that persistence of infection is a main 
determinant of cancer risk in HPV-infected women, although only 10-30% of 
infections will persist beyond 2 years (5). Persistence of HPV infection is defined as 
infection detected a number of years (such as 4-12 years) after incident infection, and it 
appears that long-term persistence of HR-HPV without development of cervical disease 
is less common than previously thought (4). The potential for latency, re-activation 
and/or re-infections with HPV is still however not fully understood (14), although 
repeated infections appear common in young women (15). 
 
HPVs are small round particles that consist of around 8 kilo-basepairs’ worth of 
circular double-stranded DNA wrapped in a protein shell composed of two capsid 
proteins (L1 and L2). Copies of these shell particles are used in vaccines to induce 
immunity to HPV (see below). Three oncogenes, E5, E6 and E7, modulate the virus 
transformation process and two regulatory proteins, E1 and E2, regulate transcription 
and replication. Together, these replicate the viral DNA and assemble newly produced 
viral particles within infected cells (11). The E1, E2 , L1 and L2 genes are particularly 
well-conserved and  HPVs are genetically very stable; sequence changes by mutations 
or recombination are very rare events (1). HPV infections are exclusively intra-
epithelial, and in the cervix infect basal cells, probably through abrasions in the 
epithelium. HPV then uses the natural differentiation of the epithelium to procreate, 
ultimately shedding complete virions while back up at the cervical surface (11). 
  
Normally, this process and the activities of E6 and E7 are tightly controlled, but in 
persistent infections the probability of molecular accidents deregulating the oncogenic 
expression in mitotically active cells can increase (13). Briefly, the neoplastic potential 
in E6 and E7 oncogenes is due to their ability to interact with human key cell cycle 
control regulators p53 and Rb. Constant E6 and E7 activity therefore confers an 
increasing genomic instability, loss of cell-growth control, and ultimately cancer. 
During progression, the viral genome frequently integrates into the host genome, 
thereby aggravating the de-regulation of oncogenes since the regulatory E2 gene is 
often lost (11). 
 
2.2 CERVICAL SCREENING AND CERVICAL CANCER 
Infection with HPV was known, but regarded as trivial until the 1970’s, when it was 
gradually discovered that mild dysplasia of the cervix exhibited the cytological and 
histological features of papillomavirus infection. In connection with this, two novel 
HPV DNA types were cloned from genital warts and classified as HPV6 and 11 (13). 
HPV11 DNA was then used by the zur Hausen group to the revolutionary discovery of 
HPV16 and 18 in cervical cancer biopsies, which gradually led to the dawn of a new 
understanding that HPV was responsible for a considerable disease burden.  
 
With an estimated half a million new cases and more than a quarter of a million deaths 
each year, cervical cancer is the third most common cancer among women globally 
(16). The median age of diagnosis is 57 years of age, compared to 72 years for other 
cancers in the U.S. (17) and cervical cancer, more than other major cancers, affect 
women under 45 years (18).  
 4 
 
Globally, the incidence varies between <3 to >50 cases/100 000 women for low- and 
high-burden countries, respectively (18). The annual incidence in Sweden is 9/100 000 
women, translating to around 460 cases, and 150 deaths each year due to the disease 
(19), despite the presence of an organized screening program with cytological (Pap-) 
smears. Following screening, the overall decrease in cervical cancer incidence has been 
~70% over a 40-year period (20) but the incidence is no longer decreasing (19).  
 
As stated above, persistent HPV infections can lead to malignant transformation of the 
cervix uteri, of varying severity. These lesions are termed cervical intraepithelial 
neoplasia grade 1-3 (CIN1-3) and may, similarly to HPV infections, either resolve 
spontaneously or progress to invasive cancer. This is a process usually spanning over 
decades but examples of more rapid progression are also known. Exfoliated cells from 
the different precancerous CIN stages can be detected through microscopic 
examination of a cytological smear using the Papanicolaou stain to dye cells – hence 
the vernacular term “Pap test”. The detection and subsequent treatment of CIN 
abnormalities forms the basis of the cervical screening programs that have substantially 
decreased the incidence of cervical cancer in industrialized countries (21).  
 
The focus in the cervical program is early detection of these precancerous changes, not 
cases of actual invasive cancer (although this is a desirable second priority) (22), hence 
programs will here mainly be termed “cervical screening” rather than “cervical cancer 
screening”. Therefore, young women are invited already at the age of 23, and screening 
continues until age 55-60. Participation in Sweden is around 80%, although slightly 
lower in those age 23-25 (65-70%) and 26-30 (~75%) (23). An individual smear can 
have a relatively low sensitivity, but this increases with repeated testing and therefore, 
three-year intervals in the program are recommended (24). In the smear; cells are 
judged according to their appearance as either normal, or abnormal of a varying degree. 
Abnormalities can be detected either in cells of squamous epithelial origin, or glandular 
origin. A combination of squamous and glandular cervical cytological abnormalities is 
possible. A cytological diagnosis which has gathered more notoriety in the past few 
years is atypical cells of undetermined significance (ASCUS), not the least since a 
seminal trial showed that the underlying prevalence of CIN3 in this group was 5% (25). 
Diagnosis of a cytological abnormality will typically lead to examination with 
colposcopy (macroscopic examination of the cervix via a gynecological exam), and 
concurrent biopsy (tissue sample) from the cervix. Every year, around 20 000 Swedish 
women receive an abnormal screening result which requires some sort of further 
investigation, and around 3300 women get a diagnosis of cervical cancer in situ (19).  
 
The ultimate potential consequence of an abnormality of squamous origin is a diagnosis 
of squamous cervical cancer in situ (CIS; where in situ refers to the cancer on 
histological examination not having broken through the basal epithelium) and invasive 
squamous cervical cancer (SCC). The ultimate potential consequence of a glandular 
abnormality is cervical adenocarcinoma in situ (AIS) and invasive cervical 
adenocarcinoma (AC). Thus, cervical cancer as a diagnosis is constituted by both SCC 
and AC, and although SCC is significantly more common, AC is increasing in the 
population (26).  
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This could be because AC is more difficult to detect on a traditional cytological smear 
since such cells derive from above the squamocolumnar junction, or transformation 
zone, in the cervix. This zone retracts further up the cervix as a woman ages, and thus 
becomes more difficult to reach with representative cytological sampling (27). 
However, no difference in cure proportions between the two diagnoses has been 
observed (22). The extent to which SCC and AC is caused by HPV has been the focus 
of numerous studies (26, 28). Attributable fraction in cervical cancer is traditionally 
calculated as the proportion of incident tumors which are HPV-positive, and for which 
HPV type (29). Using the traditional method, the attributable fraction appeared to be 
lower for AC than for SCC (27), although this could be due to artifactual explanations 
and more recent studies have detected similar prevalences of HPV in AC as in SCC 
(30, 31). 
 
Treatment of colposcopically and histopathologically verified CIN means removal of 
the lesion by preferably excision (since this yields a histopathological verification of 
radicality and nature of the lesion), but in some cases destructive techniques such as 
laser vaporization can be acceptable (32). Of note, women who have been successfully 
treated for CIN3/CIS still have a 25-year long increased risk for invasive cancer. 
Therefore, recommendations are to pay extra heed to these women (33). Treatment 
options for invasive SCC include the fertility-preserving operation trachelechtomy, 
which involves removal of the cervix and part of the vagina, but leaves the rest of the 
uterus intact. In more advanced cases, total hysterectomy and/or radiation and/or 
chemotherapy are needed (34). 
 
2.3 CANCERS IN SITES OTHER THAN THE CERVIX UTERI 
With its affinity for multiple anatomical sites, HPV has been implicated in several other 
cancers than cervical: chiefly anal, oropharyngeal, penile, vaginal and vulvar cancer. 
Around 90% of anal cancer and a smaller subset (<50%) of these other cancers are 
attributed to HPV. If this is correct, HPV would be accountable for more than 5% of the 
entire global cancer burden – the highest of all infectious agents (5). In several of these 
other cancers, it does however appear that there may be several parallel etiological 
tracks to disease. In oropharyngeal and vulvar cancer, for example, a substantial 
proportion of tumors are HPV-negative. HPV-negative disease in these cases is 
associated with factors such as a higher degree of smoking, alcohol drinking and higher 
age, whereas HPV-positive disease is associated more with sexual habits. Interestingly, 
the prognosis for non-HPV related disease appears worse in oropharyngeal cancers, for 
reasons that are not entirely understood (35). Therefore, some consider HPV-positive 
and HPV-negative tumors in these sites as different cancers (36, 37). 
 
Although these diseases are often substantially less common than cervical cancer, and 
not exclusively HPV-related, several of them afflict both women and men, and are thus 
potentially responsible for significant morbidity. Several of these cancer forms are also 
increasing in the population, such as anal cancer where a steep increase in incidence 
has been observed in both genders (38). In addition, for these other cancer forms there 
are no functioning screening programs, meaning that a viral etiology would be 




2.4 OTHER HPV-RELATED DISEASE 
As stated above, low-risk HPV types (LR-HPV) have negligible carcinogenic potential, 
but nevertheless are common and capable of causing a large morbidity burden in 
humans. A relatively common consequence of LR-HPV is condylomata acuminata 
(also called condyloma or genital warts), which has an incidence peak similar to other 
STI’s, i.e. in those age 15-24 years (39). Incidence rates in Sweden in 2007 were 
estimated at around 400 cases/100 000 for both men and women age 10-44 years (40). 
In a population-based study from the Nordic countries, 1 in 10 women had experienced 
condyloma before the age of 45, with an increasing occurrence in younger age cohorts 
(41). Condyloma is a self-limiting disease and will frequently not cause too much 
trouble, yet can lead to painful symptoms as well as stigma and shame in the patient. 
Some women and men have severe problems and may require pharmacological and/or 
surgical treatment of the warts. Therefore, although benign, the condition is associated 
with significant costs to society (41). 
 
Condyloma has been linked to subsequent risks for HPV-related cancers in several 
studies (42, 43). Obviously, this risk association could be confounded by several 
different risk factors, above all concurrent infection with HR-HPV types, the status of 
which is unknown in register-based studies (42). In fact, in molecular epidemiological 
studies that have had access to data on both LR- and HR-HPV status, an inverse 
association has been seen. Recently, HPV6 was associated with an antagonistic effect 
on the risk for cervical cancer conferred by HPV16 (44) in a seroepidemiological study. 
Whether this is a true biological effect, or caused by detection bias (due to women with 
condyloma being genitally screened more often and potentially discovered more 
frequently in the pre-cancerous stage) remains to be investigated. 
 
2.5 RISK FACTORS FOR CERVICAL CANCER 
Since most women will be exposed to HPV at some point in their life, yet only few 
develop persistence of infection and subsequent serious cervical disease, other factors 
are likely to play a role in the pathogenesis. Risk factors for (squamous) cervical 
cancer, apart from HPV infection, traditionally list early age at sexual debut; a large 
life-time number of sexual partners; use of hormonal contraceptives; high parity, 
smoking and other STI:s (44, 45).  
 
The challenge is to determine to what degree these risk factors possess an inherent 
capacity to actually induce cervical cancer, or if they are actually advanced proxy 
measures for the risk for present and/or past HR HPV infection. For example, the risk 
associated with hormonal contraceptives could be explained by a hormonal influence 
on the cervical mucosa (thus rendering it more susceptible to persistent/progressing 
infection). It could also be related to a higher risk for HR-HPV due to a concurrent 
tendency to A) use fewer condoms since already on contraception otherwise and B) 
being more likely to have an active sexual life than those not employing contraception. 
Therefore, it is important to adjust for information on these factors as well as possible, 
and in large meta-analyses, an association to contraceptive use has still been 
demonstrated (46). 
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The association between early age at sexual debut (typically before the age of 14) has 
likewise been an area of debate. Option A) could be that early age at sexual debut is 
correlated with other risk-taking behavior later on in life, for example a tendency to 
practice less safe sex (47). Option B) could be that women who start having sex early 
have more sexual partners, thus increasing the risk of contracting high-risk HPV (48). 
Again, a combination of A) and B) may exist. Yet another, very interesting, option C) 
could be that early age at sexual debut leads to early-life HR-HPV infections, that have 
the potential to last so long as to cause carcinogenesis to a larger extent than infections 
acquired later on in life. In fact, if this theory holds; it leads to convenient, if perhaps 
controversial, implications for HPV vaccination (45), which will be discussed further 
below.  
 
Smoking has been established as a risk factor for cervical cancer in several studies, 
including large meta-analyses adjusting for the other factors mentioned here (49), and a 
synergism between smoking and HPV16 status has been shown (50). Proposed 
mechanisms include local genotoxic effects in the cervical epithelium, stimulation of 
carcinogenesis, or localized immunosuppression.  Furthermore, several studies have 
noted a correlation between Chlamydia trachomatis and persistent HPV or risk of 
cervical cancer (44, 51). Finally, high parity has been shown to be a risk factor in 
developing countries, however this risk is most apparent if comparing >7 births to 1-2 
(52), meaning that few women in developed countries will be affected. 
 
So far, knowledge of these risk factors has not led to any major policy implications 
since several are difficult to modify, and confer only modestly increased risks 
compared to the risk associated with HPV. In the future, in the context of universal 
vaccination, they will likely diminish further in importance, unless vaccination fails to 
reach high-risk groups. 
 
2.5.1 Is heredity a risk factor for cervical cancer? 
Apart from viral facors, several host genetic factors, such as HLA-haplotype, might 
play a role in the cervical disease process (53). However, despite cervical cancer being 
so common, few reports exist on familial clustering of the disease. In the few reports 
there are, the observed association may be due to shared exogenic risk factors and 
lifestyles, shared genetic risk factors, or a combination of these. Several studies have 
therefore utilized family-based designs, and did find increased relative risks for first 
degree relatives of affected women (54). A Swedish study found a significantly 
increased risk of CIN3 and cervical cancer to biological, but not non-biological, first 
degree relatives of women with cervical tumors (55). These findings have however not 
resulted in any larger health policy changes so far. 
 
2.6 AWARENESS OF HPV 
HPV infection is nearly ubiquitous, yet paradoxically the symptoms are often few and 
most women will never know they had it. Despite the scientific community’s 
understanding of its role in cancer, until relatively recently HPV was not very actively 
spoken of with women, since there was no means for treating the infection except 
screen for its consequence cancer.   
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There may have been a reluctance to discuss the sexually transmitted nature of the 
cancer, to avoid stigmatizing women and causing feelings of self-blame. In qualitative 
studies, the mention of the relationship between an STI (HPV) and cervical cancer has 
indeed been shown as associated to shock among study participants (56, 57). This since 
the information seems inconsistent with the view of cancer striking an unfortunate 
victim “out of the blue” (58).  
 
In 2007, only 2.5% of a British population-based sample of women could identify HPV 
as the cause of cervical cancer without being prompted, a figure that had not improved 
much from 2002 (when it was virtually non-existent at 0.9%) (59). In 2008, the Nobel 
Prize in Physiology or Medicine was given to professor Harald zur Hausen for his 
pioneering work in the field and the publicity generated from likely helped illuminate 
the public (at least in Sweden). Further discussion has been generated by the 
introduction of school-based vaccination, where parental consent is needed. However, 
obtained study rates of awareness are highly sensitive to the phrasing of questions and 
selection of populations. Depending on study question and selection of the sample, a 
wildly varying range of HPV awareness of between 13-93% was shown in a review in 
2008 (60). Understanding of the HPV-condyloma and HPV-cervical cancer links was 
likewise inconsistent (0.6-68%, and 5-83%, respectively). More updated reviews still 
show awareness rates of between 5-66%, which means firm conclusions on the state of 
HPV awareness are continuously difficult to draw (61). Although it appears likely that 
overall awareness should have increased, there still appears to be a definite lag of 
public understanding behind rapidly advancing science (62). More population-based 
studies on these factors in both genders would be valuable. 
 
Clearly, along with the development of HPV-based prevention of cervical cancer, new 
information horizons have dawned and need to be actively and correctly communicated 
to women and men. This would be important not the least in the context of HPVtesting, 
where care needs to be taken to give correct information, while at the same time 
ensuring that it does not raise unnecessary anxiety (58). 
 
2.7 HPV TESTS 
Ever since the etiological role of HPV in cervical cancer was established, the potential 
to screen women for cervical HPV (the agent) instead of cervical cytological 
abnormalities (the symptom) has been recognized. HPV testing has long been proposed 
to replace the cytological smear as a primary screening tool – one reason is that 
identification of HPV-negative women allows reduced screening for this low risk 
group. HPV molecular testing therefore determines the need for screening, allowing a 
personalized medicine approach in programs which hitherto have been relatively 
agnostic of a woman’s past history.  
 
HPV-negative women may safely extend their screening interval to six years, instead of 
the current 3-5 years that apply for everyone regardless of HPV status (63). Recent data 
indicate that the protection conferred is valid for up to 14 years (64). Also, HPV tests 
have repeatedly been shown to possess sensitivity rates superior to those of cytology 
(65-67).  
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However, it is important to use HPV-based screening in appropriate age groups since 
transient HPV infection is so common among young sexually active women, and the 
test specificity for underlying lesions must be acceptable. The current evidence from 
randomized trials favors cytological screening until approximately age 30-35, and then 
a switch to HPV-based screening (68, 69). However, the trial results have not yet been 
transferred to clinical practice and at present HPV-tests are mainly used for triage (risk-
grading) of cytologically abnormal women (70, 71). The fact that most of Sweden has 
switched to performing cytology using liquid-based cytology (LBC), where the same 
sample can be used both for HPV typing and cytology, will greatly facilitate a 
randomized implementation of HPV screening and allow real-life studies of policy 
effects (71, 72).  
 
With the advent of HPV tests used as a triage tool in screening, indeed in the future as a 
primary screening method; improved tools for risk stratification of HPV-positive 
women are crucial. The infections are very common with approximately 10% of 
cytologically normal women being positive for HPV at any point in time (73). It has 
been estimated that almost 300 million women worldwide are carriers of HPV DNA 
(73).  Clearly, separating the few HPV-positive women at high risk for cervical cancer 
from the many with smaller risk will become a critical issue. Studies with long-term 
follow-up addressing particularly the issue of persistence of infection have been called 
for (74, 75). Also, in order to properly assess primary prevention strategies in a country 
such as Sweden, nation-specific data on the epidemiological variation of HPV are 
needed (76). Such data can provide vital clues to inform both HPV vaccination and 
HPV-based screening in Sweden. 
 
2.7.1 Adjuncts to HPV testing 
Currently, the Hybrid Capture II (HCII), GP5+/6+, Cobas 4800 and Abbott hrHPV 
PCR can be considered clinically validated assays for use in primary screening, but the 
drawback of lower specificity in HPV testing still needs to be addressed. Reflex testing 
with cytology is an effective triage method, as cytology in HR-HPV positive women 
clearly stratifies the risk of CIN3+ and cancer (67). Another established risk stratifier is 
genotyping for HPV16/18, which has a good evidence-base in terms of predicting 10-
year cumulative risk for CIN3+ (17% for those HPV16-positive, 14% for those 18-
positive, and 3% for those positive for other high-risk types than 16/18) (77). Other 
candidate markers are testing for viral RNA, p16INK4a immunohistochemistry or 
p16INK4a i67 staining (78). However, these are not yet established and should first 
show the same level of evidence as demonstrated by original HPV DNA screening tests 
(67). 
 
2.7.2 Viral load 
A special potential adjunct to HPV testing is viral load, which is the amount of viral 
DNA copies that can be detected in a cervical sample, typically normalized to the 
human DNA content in the sample. Applying a quantitative measure of HPV infection 
could present an attractive option in screening, if a reliable and consistent risk 
association with severe dysplasia could be shown. Indeed, in the year 2000, a seminal 
Swedish study was published using a nested case-control design capable of showing 
such an association for an assay measuring type-specific HPV16 viral load (79). 
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Initially rebutted by concerns that the relation was confounded by differing 
classifications of abnormal cytology (80), nevertheless multiple studies went on to 
show similar results in varying study designs and settings (81). A high viral load of 
HPV16 has since been established as a prognostic factor for cervical lesions (82-84). It 
is best measured through quantitative real-time PCR assays (85) although semi-
quantitative methods have also been used via HCII. It is conceivable to use both high 
viral load as a disease marker for women at increased risk for cervical disease, but also 
low viral load as a distinguishing sign of HPV infection at low risk of progressing (86).  
 
The clinical use of viral load is complex but if those limitations could be overcome, the 
technology could offer the benefits of increased specificity and objective, quantitative 
input to screening and management (87). However, there is a paucity of risk prediction 
data for invasive cancer. Some studies have shown conflicting results; viral loads in 
invasive cancers have either been quite low (88) or very high (89). The studies were 
also very small; only 11 and 22 cases, respectively. Another study showed no additive 
value of HPV16 viral load but only analyzed 77 cases of CIN3/invasive cancer 
combined (90). Larger studies are needed to inform this issue. 
 
2.8 HPV VACCINATION 
Along with the realization that HPV could serve as a screening tool, it was also 
proposed that prophylactic HPV vaccination potentially could reduce significant 
amounts of HPV-related disease. After much method-development, today this 
proposition has become a reality. Two HPV vaccines are approved for clinical use: the 
bivalent vaccine Cervarix (GlaxoSmithKline) and the quadrivalent vaccine Gardasil 
(Merck and Co., Inc.). The vaccines are based on the virus-like particle (VLP) 
technology, where viral genes encoding surface proteins are used to produce empty 
virus shells, capable of inducing effective immune responses without any infectious or 
malignant potential. Both the vaccines are aimed at HPV16/18 for their predominant 
role in cancer. Both have shown virtually complete protection against HPV16 and 18-
related precancerous lesions in HPV-negative individuals participating in randomized 
clinical trials with a follow-up time of up to 5 years (91, 92). Gardasil also protects 
against HPV6 and 11, which cause 80-90% of condyloma (91). 
 
Even when including previously exposed subjects (who were seropositive indicating 
past infection, but negative for cervical HPV DNA indicating no ongoing cervical 
infection), vaccination has shown protective effects in those up to age 25-26 (91, 92), 
and to some degree even up until age 45 (93). The bivalent vaccine has also shown 
significant cross-protective efficacy against HPV31, 33, 45, and 51, and against anal 
HPV infection (94, 95).  In the subset of women with signs of ongoing infection at time 
of vaccination (i.e. who are both seropositive and DNA-positive), no protective benefit 
on high-grade cervical lesions is derived (96). However, recent data indicate that the 
quadrivalent vaccine may confer protection against recurrence of HPV-related disease 
in women who had surgical treatment for such, but the mechanism behind this is not 
understood (97).   
 
It should here be noted that no effect on invasive cervical cancer has as yet been shown, 
and likely will take some time to achieve due to the long incubation of the disease. 
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Meanwhile, the shorter incubation disease CIN3 is the best surrogate endpoint we have. 
Although it is not perfect (4), CIN3 is a true precursor to invasive cancer and has an 
innate considerable propensity to progress to invasive disease (98). As such, CIN3 or 
worse (CIN3+) has been accepted by regulation agencies as an acceptable study 
outcome. 
 
Also note that the long-term duration of protection with HPV vaccines, and need for 
boosters, is quite unknown, and there is a lack of validated immunological measures of 
immunity. On a speculative note, however, if only early-life infections are relevant in 
cancer risk, a lifelong protection against HPV might not actually be necessary (45).  
 
The Swedish National Board of Health and Welfare decided in 2008 that HPV 
vaccination should be included in the national vaccination program, and administered 
to girls age 10-12 (99). The public tender was initially won by Cervarix, but after a 
complicated tender process, a new tender was won by Gardasil which will be used for 
the next few years in Sweden. Opportunistic vaccination has been available since 2006 
and was subsidized for girls aged 13-17 2007-2011. A free catch-up vaccination 
program is now available for 13-18 year olds. Approximately 130 000 Swedish females 
have been vaccinated with Gardasil, and only very few with Cervarix (100). Most of 
them have been within the 13-17 year interval but several thousand older women have 
also elected to get vaccinated. Recently, subsidized vaccination was made available for 
women until age 26, and Stockholm County Council will offer it for free until this age. 
 
HPV-vaccinated young adult women will have a continued need for screening, as 
sexually active women may have been exposed before the vaccine was given and 
effectiveness is reduced (96). Screening programs specifically for HPV vaccinated 
women will therefore need to be designed, and women’s continued participation needs 
to be monitored. Also, about 30% of all cervical cancer is caused by HPV types other 
than HPV16 and 18, and although cross-protection appears to exist, complete 
protection is not guaranteed. Second generation HPV vaccines that contain numerous 
HPV types may offer a more complete cervical cancer protection, but data from such 
trials are not yet available.  
 
In men, vaccine efficacy has been studied for the quadrivalent vaccine, and high 
efficacy against external genital lesions has been shown, although most of the 
prevented lesions were condyloma, rather than penile lesions (101, 102). In a subgroup 
study among men who have sex with men (MSM), efficacy was also high against anal 
intraepithelial neoplasia. However, penile and anal cancers are rare and will require 
long follow-up studies to determine vaccine protection (102). Modeling studies have 
predicted that the greatest benefit of HPV vaccination will be achieved through 
vaccination of girls alone, but these models are sensitive to assumptions such as 
whether only cervical cancer incidence, or other HPV-related disease, is also 
considered (102). It has been estimated that introducing a male vaccination program of 
similar coverage to that in women (71-78%) would be expected to decrease new HPV 
infections with an additional 24% by 2050, with an estimated additional long-term 
reduction in male HPV-associated cancers of 6-8% (103). However, where female 
uptake is low, it has been shown that protection against cervical cancer might be 
improved by concentrating on improving uptake in females rather than males (104).  
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A special case is MSM populations, where anal cancer is more prevalent than in 
heterosexual men, and where herd immunity derived from female vaccination is less 
likely to have a large impact. In MSM, HPV vaccination might be more cost-effective 
under certain scenarios (105). 
 
2.8.1 Efficacy versus effectiveness studies 
Randomized trials can be capable of demonstrating technical vaccine efficacy required 
for the introduction of new interventions, but they employ several selection criteria, and 
are often not fully reflective of real-life situations in which the intervention will 
actually be implemented. Studies of real-life vaccine effectiveness, and safety, is 
therefore a key component of the evaluation of HPV vaccination post-randomized 
trials. A spectrum of intermediate outcomes is available for monitoring of the early 
HPV vaccine impact, where condyloma forms a significant part, as the shortest 
incubation-disease available (106). Four years after HPV vaccination implementation, 
ecological studies have shown dramatic declines in both HPV prevalence and incidence 
of condyloma in Australia (107, 108). 
 
A recent Swedish study using a more advanced study design showed high effectiveness 
against condyloma in vaccinated women, but only if vaccinated at younger than 22 
years (100). Declines in heterosexual men have also been shown in Australia, but no 
declines among adults >30 or homosexual men (109). The partial protection in non-
vaccinated heterosexual men, probably conferred from having sex with vaccinated 
women and thus hindering spread, is commonly referred to as “herd immunity” in the 
HPV field, although it can be noted that this term in other contexts signifies the total 
protection from disease in non-vaccinated, implying having achieved a threshold of 
immunes above which no infection can persist in the population (110). 
 
2.8.2 Cross-protection or type replacement? 
A commonly mentioned concern in discussions on vaccination is whether the large-
scale removal of HPV16 and 18 will leave an empty ecological niche, ripe for the take-
over of other HR-HPV types now free to cause cervical cancer instead. For this to 
occur; two factors should be fulfilled. Firstly, there should be evidence of competition 
between HPV types, whereas in reality, multiple infections are common and no clear 
signs of type competition are apparent (5). Secondly, there should be no cross-
protection of vaccination, whereas on the contrary, quite extensive such has been 
observed (94). Thus, in combination with the knowledge that HPV has a very slow 
evolutionary process, the risk for type replacement in cervical cancer appears low, 
although the best way of proving this will be monitoring of cervical cancer incidence, 
with full HPV typing of incident tumors. 
 
2.8.3 Acceptability of HPV vaccination in different groups 
Regardless of technical advances in vaccine development, unless the target population 
is accepting of the intervention, no success will be reached in vaccination programs. 
Therefore, studies into the acceptability of HPV vaccination are called for.  
As in studies on awareness, the degree of acceptability is sensitive to setting, and thus, 
population-based studies should be a priority to improve generalizability of the results. 
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In a population-based study on Swedish parents to girls and boys age 12-15, we found 
that although awareness of HPV was low, the willingness to vaccinate one’s children 
against it was high at around 75% if the vaccine was for free.  
Vaccine safety was the most important concern (111). In line with this, a review found 
that most parents were positive towards HPV vaccination, if effectiveness was 
perceived as high, a physician recommended it, and HPV infection was perceived as 
likely (112). This review further found lower education to be associated with higher 
hypothetical acceptability among parents (a finding which concurs with ours) but also 
identified some potential controversies in HPV vaccination (112). 
 
Even though vaccination of girls before sexual debut is acknowledged as the first 
priority for national vaccination schemes, young adult women and men could also 
benefit from vaccination, as described above. Reviews in young women have found 
that acceptability overall is high (at around 50-96%), if adequate information is given, 
HPV infection is perceived as likely, and the cost is affordable (112, 113), but that 
more data from developing countries are needed (114). In men, despite low awareness 
of the virus, some or most have been willing to vaccinate, with acceptability between 
33%-78% depending on the selection of the sample. Recent data on English school 
boys reported 41% were interested in receiving the vaccine (115). Acceptability has 
been reported to be higher in MSM than in heterosexual populations (116, 117), at 
around 75% whether HIV-positive or not (118). A large majority of these studies in 
adults are however based on selected convenience samples: in a recent review, less than 
25% were population-based (119).  Therefore, caution should be exercised when 
reviewing the results, and more population-based studies appear called for. 
 
2.9 ANTICIPATED EFFECTS OF HPV VACCINATION 
In summary, organized HPV vaccination programs are today believed to result in 
reductions in the following infections and diseases around the globe: 
 
- Incident infection with HPV16/18  
- Incident infection with HPV31/33/45/51 
- Cervical intraepithelial lesions (CIN) and cervical cancer  
- Anal intraepithelial lesions (AIN) and anal cancer 
- Vulvar intraepithelial lesions (VIN) and vulvar cancer 
- Vaginal intraepithelial lesions (VaIN) and vaginal cancer 
- Penile intraepithelial lesions (PIN) and penile cancer 
- Condyloma 
For recurrent respiratory papillomatosis and some head and neck cancers, particularly 
tonsillar cancer, it is as yet unknown whether HPV vaccination will lead to decreases in 
oral HPV infection and subsequent development of these diseases, but some 
observations suggest that a protective effect might be plausible (12). The potential for 
virtually complete protection against cervical carcinoma in situ/CIN3 in unexposed 
individuals means that, under optimal conditions, in the future such a large proportion 
of both HPV, and cervical disease, could be removed from the population that it might 
be possible to speak of eradication. However, this currently remains a visionary goal, 
and we do recognize the great length of the road that still lies ahead. 
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3 AIMS OF THE THESIS 
The aim of this thesis has been to inform cervical screening practices in the era of    
HPV testing, to assist in estimating the effects of HPV vaccination, and aid in the 
development of HPV vaccination campaigns. To this end, it has involved the following 
studies: 
 
Study I: A molecular epidemiological case-control study on the risk profile of HPV 
infections, and the relative contribution of different subtypes of HPV to in situ and 
invasive squamous cervical cancer. 
Study II: A molecular epidemiological case-control study on the significance of high 
viral load of HPV16 as a risk factor in the development of in situ and invasive 
squamous cervical cancer. 
Study III: A cross-sectional survey examining awareness and knowledge of HPV in 
the adult Swedish population. 
Study IV: A cross-sectional survey examining acceptability of HPV vaccination 




Some limitations to this thesis work should be acknowledged when reviewing these 
studies.  
- The first two studies are restricted to squamous cervical cancer; 
adenocarcinoma was excluded as the two histological types exhibit different 
characteristics.  
- All studies were based in Sweden, a highly industrialized country with an 
established organized screening program that has national coverage and is 
actively offered to all women of screening ages. Therefore, the results have 
been found in a relatively privileged society where screening functions well 
and cervical cancer is uncommon, which may impact for example 
acceptability of HPV vaccination.  
- Furthermore, Study I and II use the screening program as a sampling frame, 
thus by design excluding women that do not participate. Since non-adherence 
to screening recommendations is a major risk factor for cervical cancer 
morbidity and mortality in Sweden, strictly speaking this strategy might mean 
excluding a risk group. However, in the study of screening tests such 
sampling is necessary and does not constitute selection bias. 
Note on funding: 
Study I and II were financed by grants from the National Institutes of Health, and the 
Swedish Cancer Society. The data collection in Study III and IV was funded by Sanofi 
Pasteur MSD, Sweden. All research took place independent from the study sponsors. 
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4 METHODS 
 
4.1 EPIDEMIOLOGICAL STUDY DESIGN AND ANALYSIS 
 
The goal of medical epidemiological research is frequently to make a statement about 
cause and effect in a given scenario; we aim to identify a cause of illness, to enable us 
to prevent or treat disease. Obviously, this requires a degree of causal inference so that 
we are reasonably sure of which clinical decisions on prevention or treatment to make. 
The best method to establish causality is often considered to be the randomized study, 
where subjects are randomly assigned to an exposure or not (typically a randomized 
clinical trial – RCT - exposing participants to a medical treatment or a control 
intervention). The incidence of outcome (typically disease or mortality) can then be 
studied among exposed and non-exposed, respectively, and if there is a difference, 
causality can be attributed to the exposure given all other things equal. 
 
However, in many scenarios, randomized studies are unfeasible, and/or unethical. The 
exposure of interest may not be a pharmaceutical, but instead viruses, environmental 
factors, diet, physical activity etc. We can naturally not randomize women to either be 
infected with different types of HPV, or not, and then determine who gets cervical 
cancer. In such scenarios, we frequently rely on observational (i.e. non-experimental) 
epidemiological studies instead, although they cannot prove causality (120). As this 
thesis utilizes observational epidemiological designs, some basic characteristics of 
these, and how they are analyzed, are discussed here. 
 
4.1.1 Cohort, case-control and nested case-control studies 
A cohort study describes the experience of a group of individuals followed over time, 
where both exposure/-s and outcome/-s are recorded continuously. The incidence of 
disease can thereby be studied over time, enabling calculation of the incidence rate (IR) 
at different time points. The incidence rates can then be compared in exposed and non-
exposed groups, respectively, and an incidence rate ratio (IRR) can be calculated. 
Typically, this will be interpreted as a relative risk (RR) – the risk for the outcome in 
those exposed, compared to the risk in those non-exposed. The advantage of a cohort 
study is that several different measures of outcome can be calculated, and that the study 
numbers can enable the study of rare exposures. However, if the outcome is rare, even 
large cohorts will struggle to assess that outcome effectively due to a low number of 
cases accrued. 
 
For rare outcomes, the case-control design can often be more efficient (121). As the 
name implies, a number of cases are identified through, for example, medical records at 
a clinic, an approach which ensures that a certain number of cases are met. A number of 
controls (i.e. subjects without the disease) are selected as a comparison group, although 
defining controls representative of the entire population at risk can be challenging and 
may succeed to varying degree. Then, exposure status is assessed, through either 
objective sources such as health registers, or subjective sources such as the cases and 
controls themselves (through questionnaires, interviews, etc).  
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To increase precision, several controls per case may be selected, where four is usually 
considered optimal (122). However, since the proportion of cases in the study is pre-
determined by the investigator, and the time to event is not known, the IRR cannot be 
estimated. Instead, the odds ratio (OR) is estimated, where the odds of being a case if 
exposed are compared to the odds of being a case if non-exposed. The possibility of 
this may appear counterintuitive, since the probability of being a case in the study is 
what is known at the outset (as the ratio of cases to controls is determined by the 
investigator), whereas the exposure status is not. However, based on Bayes theorem, 
conveniently the OR of having disease if exposed is the mathematical identity of the 
OR of being exposed if having disease, an important foundation for the case-control 
study. A further advantageous feature of the OR is that, if the outcome is rare, the OR 
will approach the RR estimate (123), thereby under the “rare disease assumption” 
enabling the interpretation of the OR as a relative risk, which is often easier to 
communicate.  
 
The nested case-control study was proposed as lying in the intersection between these 
two study designs. All cases and controls, after all, originate in a population of some 
sort, and it was gradually realized that case-control studies can be viewed as nested 
within a larger population or cohort. Frequently, this cohort is ill-defined, but in 
instances where it can be more closely detailed, it is possible to construct a case-control 
study which is clearly nested in, and preserves the validity of, the underlying cohort.  
Briefly, this requires defining a cohort of subjects who are closely followed until 
development of disease, with accurate registration of follow-up time. When disease 
occurs, that subject becomes a case, and at that time, from all the remaining subjects 
still at risk for the disease (i.e. the risk-set, those not dead, emigrated or censored for 
other reason), controls are randomly selected. Since the controls are randomly sampled 
from the remaining population, their experience of exposure (or non-exposure) is 
considered representative of the remaining risk-set.  
 
Controls are therefore selected from the person-time at risk, and matched on time to the 
cases (121), meaning that the OR will be a good approximation of the IRR from the 
corresponding cohort study, although with lower precision inherently due to the 
sampling procedure of controls (124). This precision deficit can be improved if 
sampling a greater ratio of controls to cases than 1:1. This way of sampling controls – 
incidence density based – further entails that the rare disease assumption is not required 
to interpret the OR as a IRR (124) although there are some limitations to this statement 
(125). With accurate knowledge of the sampling fractions, it is also possible to estimate 
the absolute risk (AR) for the outcome from a nested case-control study, a measure 
otherwise reserved for cohort studies (126). 
 
The nested case-control study is particularly appealing for studies on molecular 
epidemiology, which combines traditional register-based variables with biological 
measurements (127). This was a main motivation for using the nested design in our 
Studies I and II. The study base required to yield the desired number of cases exceeded 
one million women: performing a cohort study with full HPV typing in this population 
would obviously be impossible. The nested design instead allows a methodologically 
sound and cost-effective approach while also maximizing the number of cases available 
(124). 
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In all types of studies mentioned above, the collection of data on exposure can be either 
prospective or retrospective. Prospective refers to data collection which took place 
before the outcome was known. We have therefore termed Study I and II “prospective”, 
since they measure HPV prevalence in archival smears taken and stored in the years 
before diagnosis of disease. Thus, we were able to objectively assess HPV status before 
the outcome was known. “Retrospective” refers to data collection performed when it is 
already known who is a case and who is a control in the dataset; the classical example 
perhaps being a questionnaire assessing previous exposure to risk factors for a disease 
which the study subjects answer themselves. Such a retrospective data collection may 
be more prone to biases such as recall bias (see below) than a prospective such, but it 
should be noted that retrospective does not necessarily mean worse quality of the data. 
 
4.1.2 Cross-sectional studies 
Cohort and nested case-control studies are longitudinal in nature: exposure and 
outcome can be separated in time. Depending on the research question, study designs 
without a time dimension can also be informative. For example, many survey studies 
are cross-sectional in nature: the outcome of interest can be current opinion 
(“outcome”) on some matter, and what factors (“exposures”) may be related to that 
opinion. The design aims to provide a “snapshot” of the population at that time, not to 
calculate incidence of outcome/disease over time (124). The measure calculated in a 
cross-sectional study is typically an odds ratio, sometimes called prevalence (rather 
than an incidence) odds ratio to emphasize the cross-sectional aspect. For Study III and 
IV in this thesis, the question of interest was to which degree respondents were 
currently aware of HPV, and willing to vaccinate against it. For this purpose, a cross-
sectional study design was deemed appropriate. However, this design also places 
restrictions on how associations can be interpreted (see below), and for that reason we 
termed the independent variables “correlates” rather than “exposures”. 
 
4.2 ERRORS IN EPIDEMIOLOGICAL RESEARCH 
 
4.2.1 Systematic error 
The overriding issue in observational epidemiology is that there is no randomization 
procedure to confer protection against systematic error in the estimation of the effect of 
exposure on the risk of outcome. In reality, subjects are not randomized to exposure or 
non-exposure and all other factors are not equal: many may vary systematically 
between exposed and non-exposed, and in those with the outcome and without. Thus, 
exposure and outcome may share (other) common causes, which will induce a spurious 
association between the two, even though there is no causal relationship between them. 
Such a spurious association is termed confounding (120). Common confounding factors 
are gender and age but in general, confounding is unique to each situation and deciding 
on which confounders may be relevant requires detailed subject matter knowledge. 
 
Briefly, some methods for handling confounding are implemented on the design stage, 
such as restriction and matching (others are implemented at the analysis stage, see 
further below). Restriction entails restricting the study population to, for example, one 
gender.  
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Thus, gender is constant across exposure and outcome and cannot confound the 
estimates of the effect. Matching is another way of holding certain factors constant 
between cases and controls: for each case, controls are selected not entirely randomly, 
but so that they match the case in terms of e.g. age and living area. Done judiciously, 
matching can remove confounding and increase efficiency in estimating an effect of 
exposure and outcome, but this also means that an effect for the actual matching 
variable/-s cannot be calculated – which is why care should be taken not to match on a 
variable which may later be of interest. Also, the analysis must always take the 
matching factors into account, or the estimate will be biased (128). Further, it should be 
emphasized that matching to a degree will force cases and controls to be more alike in 
the study than in real life, which means that matching on too many variables may 
induce bias rather than prevent it. Study I and II in this thesis were matched designs, the 
reasons for which are discussed below. 
 
Another systematic error of note is selection bias, where the effect of exposure on 
outcome is different among those who participate in the study, than those who do not. 
The association in those who do not participate is usually unknown, and presence of 
selection bias is usually therefore inferred, rather than observed (124). In Study I and II 
below, we discuss whether there is such selection bias affecting whether our results are 
generalizable to the wider population or not. In Study IV below, we attempt to formally 
investigate non-participation to the study, and whether it can be adjusted for via a 
separate analysis. 
 
Thirdly, misclassification bias concerns the crucial part of an epidemiological study of 
classifying subjects regarding exposure and outcome status. This classification is the 
“alpha and omega” of any research study, yet there is frequently the risk of getting it 
wrong. Misclassification of exposure can be non-differential with respect to outcome 
status, i.e. equally present whether the subject is a case or not. This will tend to bias 
obtained estimates towards the null, i.e. an attenuate the effect. If the misclassification 
is unequally distributed with respect to outcome status (differential misclassification), 
this will either exaggerate or underestimate an effect and the direction may sometimes 
be difficult to predict (120). A classic case of differential misclassification is recall 
bias, where individuals with a disease recall exposure in a systematically different way 
from those that never suffered from disease. Additionally, there can be non-differential 
or differential misclassification of outcome in relation to exposure status. In our Study I 
and II, outcome status (cervical cancer) was registered in the Swedish Cancer Register 
with no knowledge of exposure (HPV) status. Exposure (HPV) status was determined 
by laboratory technicians who were blinded to outcome (case/control) status.  
 
4.2.2 Random error 
The goal of most epidemiological studies is to reflect the real life (“true”) estimate that 
would have been obtained if exposure-outcome relation could have been studied in the 
whole population, rather than just a sample of it. After all, if another study had been 
conducted on another sample from the same underlying population, it may have 
reached a different result. Thus, we must account for how likely it is that our observed 
result arose merely as a result of sampling variability.  
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For this reason, we do not only report point estimates of our effect measure (such as 
OR=2), but we also consider the risk for random error in our study, chiefly through the 
use of confidence intervals (CIs). The CI is constructed as the sample (point) estimate 
plus or minus its standard error (SE) multiplied by an appropriate percentage point 
(based on a normal distribution unless the sample size is small). Typically, the SE is 
multiplied by 1.96 to yield a 95% CI. The CI gives a range of values within which we 
are reasonably confident that the true population difference lies (123). For example, the 
OR for an exposure related to an outcome could be reported as 2.0 (95% CI 1.8-2.4). 
CI:s are used regardless of the type of outcome measure used (OR; RR; IRR, etc.). The 
SE also determines the test-statistic, which is used to derive the p-value for the 
association. The larger the test statistic is, the smaller the p-value becomes. The p-value 
is usually interpreted as the probability of the observed result, even though the null 
hypothesis of no difference between exposure groups is true. Hence, the smaller the p-
value, the lower the probability that the results arose by chance (123). 
 
The SE is inversely related to the sample size and will thus be smaller as the study 
increases in size, which means that with increasing size, the CI becomes tighter and the 
p-value smaller. With infinite size, the study’s random error would be removed as the 
sample estimate would be the same as the population estimate (124). Indeed, this has 
been the motivation for some to debate the use of CI:s when considering whole 
population data such as national cancer registers. However, even national registers can 
be considered samples from the population, and a CI is then usually an appropriate 
caveat (129). 
 
The CI and p-values are naturally related, as they are both derived from the SE. 
Together, they constitute measures of precision in the study. All the studies in this 
thesis report CI:s, Study III and IV also report p-values for some or all associations. 
Study III and IV state the use of a convention of considering p-values <0.05 as 
significant (the equivalent of a 95% CI not containing the null value). However, the 
CI:s were naturally also taken into account. 
 
4.2.3 Logistic regression modeling 
In epidemiology, we frequently wish to conduct analyses considering several exposures 
at once, rather than just one exposure and outcome. A flexible analysis method for 
estimating effects, and controlling confounding due to several variables, in case-control 
and cross-sectional studies is the logistic regression model (123). It is similar to linear 
regression, but considers a binary outcome (e.g. cervical cancer yes/no, accurate 
knowledge of HPV yes/no) instead of a linear one. It estimates the probability of 
outcome Y given exposure x: P(Y=1│x), also expressed as π. This probability is 
transformed to a logit function (hence the name logistic regression):  
             
Logit[π] = log(π/(1- π)) = log(odds) = β0 + β1x1 
 
Where β0 is the baseline log odds for the outcome in the unexposed and x1 equals 1 for 
those in the exposed group and 0 in the unexposed group  (130). The transformed 
logit[π] has many of the desirable properties of a linear regression model; it can be 
continuous and range from -∞ to +∞. (Note: “log” here refers to natural log, not log10.) 
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The interpretation of the formula above is that when exposure x1 increases by one unit, 
the log odds of the outcome will increase by β1. This assumes linearity of the logit, an 
assumption which should be investigated. If needed, this assumption may be relaxed by 
categorization of a continuous exposure variable or by the use of methods such as 
splines (131), which were used to model HPV16 viral load in Study II. 
 
The logistic regression model conveniently extends to accommodate exposures with 
more than one level, and to consider more than one exposure (terms β2x2…βkxk are 
added, leading to a multivariate analysis). When the parameter β1 is back-transformed, 
it yields the desired odds ratio for exposure x1 (in a multivariate analysis adjusted for 
the other variables xk included), along with a CI and p-value for the effect. The logistic 
regression model with a binary outcome can also be extended to consider instead an 
outcome with three or more levels. The model then estimates the effect of one or more 
exposures on the probability that the outcome is in a certain category (123). This is 
termed multinomial logistic regression, used in Study III to determine willingness to 
vaccinate a) not at all, b) only if for free or c) even if at a cost. 
 
If a case-control is individually matched on certain factors, these factors should be 
taken into account in the analysis in order not to bias the effect estimates. The standard 
approach is to use conditional logistic regression, a variant of logistic regression where 
the pairing of cases and controls is preserved in the analysis (123).  
 
Unconditional OR  =  odds of outcome in exposed group  
              odds of outcome in unexposed group  
 
Conditional OR      =  ratio of discordant pairs  
           =  no. of pairs in which case exposed, control not exposed 
               no. of pairs in which control exposed, case not exposed  
 
Concordant pairs on the exposure contribute no information; only pairs discordant for 
the exposure do. If data on a case or a control is missing, this means that information 
from the pair is lost, and if only few discordant pairs are available in the analysis, 
precision will be low. It is possible to break the matching and manually adjust for the 
matching factors, although care must be taken to compare the estimates from the 
matched and non-matched analysis to ensure that bias is not introduced (128). We have 
however chosen to consistently employ the standard approach of conditional logistic 
regression in Study I and II which were matched, and accept that this may lead to a loss 
in precision.  
 
Another advantage of multivariate logistic regression modeling is that it allows the 
assessment of interaction effects in the data. Interaction, or effect modification, is not a 
confounding effect (i.e. inducing a spurious association between exposure and 
outcome), but a true effect that may be of interest to examine (122). Effect modification 
means that the OR for the outcome in the exposed differs according to a third variable, 
such as gender. If no interaction terms are included in the logistic regression model, it is 
assumed that no such interaction exists. We actively investigated interaction effects 
with multiple HPV type infections in Study I, and interaction effects with gender in 
Study III and IV. 
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4.3 INTERNAL AND EXTERNAL VALIDITY 
 
Finally, some brief words on the concepts of study validity, which are frequently 
discussed in epidemiological contexts. As reviewed by Steckler and McLeroy (132), 
different types of validity of a study have been defined; such as 
  
1. internal validity (whether the study correctly estimates what it aims to 
estimate)  
2. statistical conclusion validity (whether statistical conclusions made in the 
study are justified)  
3. construct validity (whether operational variables adequately represent 
theoretical constructs)  
4. external validity (whether (causal) relationships can be generalized to other 
populations and times)   
 
Statistical conclusion validity and construct validity can be considered parts of internal 
validity, a key feature of which is the quality of design and measurements in the study. 
Our ability to generalize the findings, i.e. the degree of external validity in the study, 
may be more dependent on judgment (132). A high internal validity is usually 
considered a prerequisite for high external validity, but is not a guarantee for it – as 
demonstrated by the difference between the results in even very high-quality RCT:s 
once applied in less selected populations (133, 134). Therefore, RCT:s and 
observational studies complement one another. Perhaps a suitable axiom in this case 
would be the following, as paraphrased from Nallamothu et al (134): 
 
“All types of evidence for new therapies [or exposure-outcome associations, author’s 
note] rely primarily on the rigor with which individual studies were conducted, 


















4.4 REGISTERS USED IN THIS THESIS 
• The National Cervical Screening Register (NCSR) 
Initially established ten years ago at MEB, KI, the NCSR is a highly reliable quality 
register with 100% coverage of new smears. Encompassing screening information back 
to the late 1960’s, it contains records of over 15 million cervical smears and 2.5 million 
histological samples, from around 3.3 million Swedish women. In 2011, the register 
was transferred to the auspices of Stockholm County Council (23), and now forms part 
of the National Quality Register for Cervical Cancer Prevention. This register is led by 
a national steering group with complementary expertise in epidemiology, gynecology, 
pathology, virology and oncology. Evaluation of data delivery, coverage and multiple 
quality indicators is carried out annually, enabling bilateral feedback.  
 
• The Swedish Cancer Register (SCR) 
The SCR was founded in 1958 and is maintained by the National Board of Health and 
Welfare. It has national coverage and reporting of malignant and certain benign tumors 
is compulsory to the register from the health care provider, via six regional cancer 
registries around the nation. A cancer report has to be sent for every cancer diagnosed 
at clinical, morphological and other laboratory examinations, and those diagnosed at 
autopsy. In a validation study, the completeness of the Register was evaluated formally 
for the year 1998, through comparing all cases in the Register to those in the National 
Hospital Discharge Register. It was found that the overall completeness of the SCR is 
high and although there is some underreporting, this rate was very low for female 
genital cancers (135). 
 
• The Swedish Total Population Register (TPR) 
The TPR is maintained at Statistics Sweden, the national Swedish statistical agency. It 
contains information on every resident registered in Sweden at the end of each year 
since 1968. Each individual is recorded through a unique personal identification 
number (PIN). Data on births, deaths, immigration, emigration etc. are reported from 
local taxation authorities to the register continuously, and after 30 days the coverage in 
TPR is nearly complete, although slightly lower for emigration statistics (136). 
 
• The Longitudinal Integration Database for Health Insurance and Labor 
Market Studies (LISA) 
This is a longitudinal database at Statistics Sweden which integrates data from the labor 
market, educational and social sectors and which is updated each year. Abbreviated 
LISA in Swedish, it includes among others, information on employment, disposable 
income, country of birth, country of parental birth, education, and residence (137). 
 
Register linkage procedure 
These databases were all linked through the individually unique Swedish personal ID-
numbers, which allow for linkage through virtually 100% of the Swedish health care 
system (138).   
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4.5 METHODS IN STUDY I AND II 
In these first two studies, the following study questions regarding risk for cervical 
cancer in situ (CIS) and invasive squamous cervical cancer (SCC) were posed: 
 
- What is the category-specific risk associated with different HPV type 
infections? 
- What is the effect of persistent infection with HPV16? 
- What are the predicted effects of the current and future HPV vaccines? 
- What is the risk associated with HPV16 viral load? 
As described above, a nested case-control study using archival cervical smears was 
deemed appropriate for answering these questions, since ever after the development of 
a validated laboratory method for such smears (139); this observational study design 
has been used in Sweden with great success (79, 140).  
 
4.5.1 Classification of outcome 
Study I and II: Sampling frame and study participants 
 
For Study I, our initial source population comprised all women who participated in 
Swedish cervical screening sometime during 1969-2002, n=757,690, in a number of 
county laboratories. For Study II, this source population was expanded to include 
1,459,258 women. For each study, we then identified a cohort of women whose first 
registered smear (defining cohort entry) was classified as cytologically normal (Study I: 
739,072 women, Study II, 1,431,724 women).  
 
For each study, the cohort was subsequently linked to information from the Swedish 
Cancer Register (SCR) to identify all women with a first histologically confirmed 
diagnosis of cancer in situ (CIS) or invasive squamous cell carcinoma (SCC) after 
cohort entry. A diagnosis of CIS in the SCR translates internationally to a diagnosis of 
CIN grade 3 (CIN3).  Since the incidence of CIS is higher than the incidence of SCC 
(19, 141, 142), we included only a random sample of CIS to achieve case-groups of 
more similar size.  
 
To be eligible as a control, a woman could not have had a histologically confirmed 
diagnosis of CIS/SCC at the time of diagnosis of the case, i.e. she must still be at risk. 
Among all eligible control women (i.e. the entire at-risk-set), one control woman – 
matched on county laboratory, date of cohort entry (+/- 3 months), and age at first 
normal smear (+/- 1 year) – was randomly selected for each CIS and SCC case. (Nota 
bene: since she is still at risk, a feature of the nested case-control study is that a control 
may later become a case, however this only occurred in one control woman from the 
CIS group, and none in the SCC group.) Since both the HPV exposure and risk of a 
CIS/SCC outcome may vary systematically over age and time period, this matching 
was done to minimize confounding from these factors. The matching on county was 
implicit from a logistical perspective as biobanks agreed to the study on a county 
(laboratory) level. 
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All available smears from the case patient and the control woman taken prior to the 
date of diagnosis of the case were retrieved from biobank archives included in the 
studies.  
 
4.5.2 Ascertainment of outcome 
Study I and II: Histopathological re-review 
 
To verify the original histological diagnosis, all available histological specimens from 
the case women were re-reviewed by one senior pathologist. Due to the multiplicity of 
pathology laboratories involved (in total 38 such), the overall proportion of missing 
histologies in this study was 18% for SCC and 21% for CIS. Given our nation-wide 
approach and our study time spanning several decades, we hold this to be acceptable 
given that our previous study had a missing rate of 11%, in just one county laboratory 
(79). In several instances, we contracted laboratories to re-section new cases from old 
paraffin-embedded tissue since the original slides had been disposed of. On several 
occasions, due to sparsity of material to re-section, our pathologist was not able to 
review all original tissue blocks representatively. It is therefore not certain whether all 
the cases that were re-classified as lower-grade (than originally) truly are of lower 
grade. It could also be that our pathologist was not able to review them to the same 
precision as the original diagnostician.  
 
Usually, it is the epidemiological tradition to exclude all cases that were not confirmed. 
However, all cases in the study were originally histo-pathologically verified. The 
reduced power due to missing histological re-review, and partially unclear validity of 
the reclassification, means that we therefore hold sensitivity analyses, comparing 
results in the full and the re-classified data, to instead be the most informative.  
 
4.5.3 Classification of exposure 
Study I: Qualitative infection with HPV 
 
Each archival cytological smear was re-coded and re-labeled to ensure blinding of case-
control status to the analyzing staff; samples belonging to the same matched case-
control pair were included in the same analysis batch at the same calendar time. DNA 
extraction was performed by validated methods (139). All smears were analyzed for the 
presence of seven low-risk HPV types (HPV 6, 7, 11, 42, 43, 70, and 90), and 16 high-
risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82).  
The polymerase chain reaction (PCR) amplification of a consensus region using 
GP5+/6+ primers (143) was followed by HPV type detection through a PCR-EIA 
(enzyme immunosorbent assay) and reverse dot blot hybridization procedure (RDBH) 
(144) or detection of biotinylated HPV amplicons by a multiplex fluorescent bead-
based assay (145). Positive controls (HPV16 DNA) and multiple negative controls 
(Sigma water) were included in all runs to ensure absence of contamination.   
Presence of amplifiable DNA in samples was determined by PCR-EIA or real-time 
PCR for the housekeeping β-globin gene.  
 
HPV analyses were performed in the WHO HPV LabNet Global Reference Laboratory, 
Malmö, Sweden.  
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Study II: Quantitative infection with HPV16 
 
Study II focuses on risk for CIS and SCC according to infection with HPV16 measured 
quantitatively (i.e. amount of infection, not just infection present yes/no). In HPV16-
positive samples, the viral load was measured as an absolute number of viral copies of 
the E7 gene per microliter, using the Taqman real-time quantitative PCR method (146). 




4.5.4 Statistical methods 
Study I: Data structuring and model construction 
 
Study I focuses on type-specific risks for CIS and SCC according to category of HPV 
infection measured qualitatively (infection present yes/no). In all studies concerning 
HPV type-specific risks, some decision must be made as to how to handle multiple 
infections, which are usually present to at least some degree. This decision will depend 
on the research question involved. It is possible to handle multiple infections either at 
the exposure classification stage (147), or the modeling stage (66).  
 
For the purpose of our study, we defined exposure categories as follows: (a) HPV16, 
the first/last smear being positive for HPV16; (b) HPV18, the first/last smear being 
positive for HPV18; (c) HPV16/18, the first/last smear being positive for HPV16 
and/or 18; (d) non-16/18 HRHPV, the first/last smear being positive for one or more 
HRHPV types but not HPV16 or 18; and (e) LRHPV, the first/last smear being positive 
for one or more LRHPV types. We thus chose to treat multiple infections first at the 
classification stage, which meant that many of the multiple infections were handled by 
grouping. However, some women were still positive for two categories in the same 
smear and thus, further refinement was required.  
 
For estimating odds ratios associated with each category, taking the effect of multiple 
categories into consideration, we constructed a conditional logistic regression model 
including terms for the main effect for each category, and terms for possible two-way 
interactions between them (it was not possible to analyze three-way interactions due to 
a lack of power). The following model was fitted: 
 
Logit (Y=1│16/18 HRHPV, non16/18 HR HPV, LRHPV)= β0 + β1HPV16/18 + 
β2non16/18HR HPV + β3LRHPV + β4HPV16/18* non16/18HR HPV + β5HPV16/18 * 
LRHPV + β6non16/18HR HPV* LRHPV 
 
In this analysis, the main effects (reported in the paper) represent the risk association, 
adjusting for multiple category infections. This estimation requires using HPV-negative 
women as a reference level, since only they are free of all possible combinations of 
HPV-positivity. When studying a single HPV type, use of an HPV-negative reference 
level – instead of women negative for only that HPV type – will inflate odds ratios 
compared to a mixed reference level (which is why we also present results for a mixed 
reference level, “all other women”).  
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In our case, however, this use was called for in order to obtain etiological fractions for 
non16/18-HR HPV free of contamination from concurrent 16/18-infections.  
 
We also examined HPV16 persistence as an exposure in this study. Persistence of 
HPV16 infection in the first two consecutive smears was defined as: (a) negative (both 
smears negative for HPV16); (b) transient (first positive, second negative); (c) acquired 
(first negative, second positive); or (d) persistent (both smears positive for HPV16).  
All risk associations with the exposure were analyzed separately in the first and in the 
last smear prior to the diagnosis of the case, to describe changes in risk over time to 
diagnosis. As discussed above, the ORs obtained in this study (and Study II) are 
interpretable both as the IRR and the RR. We do not explicitly mention the IRR in the 
articles since it was judged that a relative risk interpretation was the most 
communicable in either case. 
 
Attributable risk proportions (ARPs) and 95% confidence intervals (95% CI) were 
calculated based on ORs obtained from the conditional logistic regression models 
(148). The formula used was the following: 
 
ARP = pd((RR-1)/RR) 
 
where pd is the proportion of cases exposed to risk factor, and RR is the adjusted OR 
for the main effect in each category of HPV-positivity, retrieved from the conditional 
logistic regression models (for a discussion of different formulas for ARP, see also 
(149)). 
 
We performed sensitivity analyses using histologically re-confirmed cases only. In 
these analyses, the results remained robust. 
 
Study II: Data examination and model construction 
 
For our study II, we focused on HPV16 viral load and began with evaluating multiple 
time scales for their relevance for the dynamics of HPV16 viral load. Because control 
women had few HPV16-positive smears, we modeled viral loads among case women 
only. We fitted linear models for the logarithmized (base 10) viral loads with time 
before diagnosis as primary time scale; and then systematically added individual and 
combined age, period and cohort (APC) effects to the basic model. 
  
These effects were evaluated both for their statistical significance and size. These 
preliminary models indicated weak or no effect of birth cohort and age at smear on 
viral load in either case group. However, we did find a significant effect of calendar 
period of smear for CIS, where viral loads decreased systematically over time: the 
highest levels were found during the 1980s, with levels at the end of the 1990s almost 
an order of magnitude lower. Sensitivity analysis indicated that this period effect 
affected risk estimates for CIS, but not for SCC; consequently, only viral loads for CIS 
were adjusted for period of smear.  
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Independently of these adjustments, we also found that viral loads for cases and 
controls varied systematically within the period of HPV analyses, with later 
measurements tending to be lower during the analysis period (2005-2010). 
Consequently, all viral loads were adjusted for calendar date of analysis.  
 
 Risk estimation through viral load imputation 
 
We used conditional logistic regression (as defined above) to study the association 
between HPV16 viral load and risk of CIS and SCC at 1-10 years prior to diagnosis, 
using HPV16-negative women as reference. A practical consideration when modeling 
the risk associated with viral load cross-sectionally over time was the irregular pattern 
in which smears were available due to our study being nested in a screening program 
with variable participant compliance. This meant that few matched case-control pairs 
originally had measurements in the same intervals. As a consequence, only few 
matched pairs would contribute to the estimation of each cross-sectional odds ratio, 
leading to wide confidence intervals and problems with separation. To address this 
issue, we implemented a within-person imputation scheme for each individual, as done 
previously by our group (79). For each subject and each year, we imputed HPV16 
measurements from all observations within a fixed window (±5 years), where 
observations closer in time received larger weights.  
 
Formally, this entailed that for any individual with observed HPV16 status Y1 , . . . Yk 
and corresponding viral loads L1 , . . . Lk  at time points t1 , . . . tk , we estimated the 
probability of being HPV16 positive at any time point t as  
𝑝𝑝(𝑡𝑡) =  ∑ 𝑌𝑌𝑖𝑖/𝑑𝑑𝑖𝑖𝑑𝑑𝑖𝑖≤𝑤𝑤
∑ 1/𝑑𝑑𝑖𝑖𝑑𝑑𝑖𝑖≤𝑤𝑤  
 
where di=|t-ti | is the absolute distance from the target time point to the observational 
time points, and w is the width of the time  window. For an empty window, the 
corresponding probability and measurements were set to missing. For a single 
imputation run, we used p(t) to impute Y(t) at yearly intervals up to 15 years prior to 
diagnosis or up to first smear. For an imputed HPV16-negative smear, the 
corresponding viral load L(t) was set to zero; for an imputed positive smear, the 
corresponding viral load was selected randomly from the observed loads Lj within the 
current time window,  with selection probability proportional to distance in time: 
𝑝𝑝𝑗𝑗 (𝑡𝑡) ~ 1/𝑑𝑑𝑗𝑗  
 
with a large finite value substituted for dj=0.    
 
For the final results, we performed 100 imputation runs for all individuals, resulting in 
100 imputed data sets. The final estimate of the odds ratio at each time point t was 
calculated as the average of the estimates from the imputed data sets.  
The corresponding variance was calculated as the sum of the average of the within-
imputation variance and the between-imputation variance, according to Rubin’s 
formula (150). Alternative values of four and six years for the imputation time window 
w had little effect on the results.  
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We used a marginal mean approach to modeling longitudinal effects in the viral loads 
of case women and the risk of cervical cancer associated with HPV16 viral load. 
Individual trajectories of viral load in women with multiple smears can vary 
substantially, which is why we opted for the per-subject imputation scheme outlined 
above for estimating risk. Our results are consequently valid and interpretable on an 
average population level.  
 
We performed sensitivity analyses using histologically re-confirmed cases only, and 
analyses restricted to the pre-1995 period. The results remained robust in these 
analyses. 
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4.6 METHODS IN STUDY III AND IV 
The main research questions for these studies were 
 
- What degree of awareness of HPV was there in the Swedish population pre-
large scale HPV vaccination campaigns? 
- What degree of correct knowledge did people possess regarding HPV? 
- How many are willing to vaccinate against HPV? 
- What are the concerns regarding HPV vaccination? 
- Might some health behaviors change after HPV vaccination? 
For these questions, a cross-sectional study assessing current opinion was deemed 
appropriate, building on previous experience from similar survey studies on condyloma 
(41, 151). 
 
4.6.1 Sampling frame and study participants 
Study III and IV 
 
Study III and IV are based on a nationwide population-based cross-sectional survey in 
two demographic groups: parents to children aged 12-15, and young adults aged 18-30. 
The rationale for this was that parents will make decision regarding school vaccination 
for their children, but young adults will participate in, or make their own decisions 
regarding, catch-up vaccination. The first group consisted of 20 000 parents of children 
aged 12-15 years (16 000 parents to girls and 4000 parents to boys) and the second 
consisted of 20 000 young adults aged 18-30 years (16 000 women and 4 000 men). 
Parents to girls and young women were purposefully over sampled since they constitute 
the main target of HPV vaccination and to enable adequate power in a planned follow-
up study. Both groups were randomly selected from the Swedish Population Register 
from which home address and telephone number was retrieved, which were used to 
contact the study sample. 
 
In Study III, both the parents and young adults were included. Study IV focuses on 
young adults only, as acceptability among parents had already been assessed separately 
(111). 
 
4.6.2 Survey data collection  
 
Study III and IV 
 
The survey was conducted during January to May, 2007. A multi-modal method for 
data collection was used to improve response rates to the study. First, an invitation 
letter was sent out which included a log-in to a web-based form of the questionnaire. If 
no response was made, participants were reminded by post two more times (three 
weeks apart) and given opportunity to also respond by a paper-based questionnaire in 
the first reminder and by a telephone interview in the second reminder. Participation 
was voluntary and by answering the questionnaire, subject consented to take part in the 
study.  
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In order to examine survey non-response; additional socio demographic data on the 
entire initial sample including non-respondents was obtained from the LISA database at 
Statistics Sweden, after de-identification of the data. 
 
In the parents’ group, the questionnaire recorded information on demographic factors 
(section 1), awareness and knowledge of HPV and HPV-related diseases (section 2), 
attitudes toward vaccines in general (section 3) and acceptability and perceptions of 
HPV vaccine (section 4). They were also asked at the end of the questionnaire whether 
HPV vaccination might alter children’s future health-care related behavior (section 5). 
In the young adult group, the questionnaire recorded information on demographic 
factors (section 1), sexual habits (section 2), awareness and knowledge of HPV and 
HPV-related diseases (section 3), attitudes toward vaccines in general (section 4) and 
acceptability and perceptions of HPV vaccine (section 5). Female respondents were 
also asked questions on awareness of and participation in cervical screening, and 
intention towards screening if they were to be vaccinated against HPV (section 6).  
 
4.6.3 Classification of exposure 
Study III and IV 
 
As this was a cross-sectional survey, it should be noted that there are no absolute 
boundaries between what is considered exposure (cause) and what is considered 
outcome (effect) in the study. Technically speaking, that would require causal inference 
which is not possible without exposure and outcome being separated in time. In both 
Study III and IV, many different variables were considered regarding potential relation 
to the outcome (knowledge of HPV in Study III and acceptability of HPV vaccination 
in Study IV), but since the study was cross-sectional in nature, we have consistently 
opted to term these variables “correlates” to the outcome, rather than “exposures”.  
Many potential correlates were assessed in both studies, and these can be grouped into 
a) socio-demographic variables, b) variables describing sexual habits (only in young 
adults) and c) awareness of HPV and HPV-related diseases. The socio-demographic 
variables mainly utilized the data from Statistics Sweden, but were in some cases also 
complemented by questionnaire data. Variables were selected into the model based on 
prior knowledge and potential association with the outcome. 
 
4.6.4 Classification of outcome 
Study III: Awareness and knowledge of HPV 
 
HPV awareness was assessed in section 2 (parents) or 3 (young adults) by an item 
asking “Had you heard of a virus called human papillomavirus (HPV) prior to your 
participation in this study?”. Correct knowledge was assessed by asking respondents 
who had heard about of HPV if they thought that 1) HPV can cause cervical cancer, 2) 
HPV can cause other cancers, 3) HPV can cause condyloma (a.k.a. genital warts), 4) 
HPV is sexually transmitted, 5) men can be infected with HPV and 6) women can be 
infected with HPV. All questions could be answered with “Yes”/”No”/”Don’t know”. 
An HPV knowledge score was then constructed, where the respondent was given one 
point for each correctly answered question (the correct answer to all questions was 
“Yes”). The range was therefore 0-6 points.  
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Persons who had not heard of HPV were given 0 points in the analysis. Please note that, 
whereas some tend to use the term “awareness” and “knowledge” interchangeably, 
strictly speaking: “awareness” refers to having heard of something (as in being aware 
of something) whereas “knowledge” signifies correct understanding of an issue (as in 
ability to answer specific questions on the topic).  
 
Study IV: Acceptability of HPV vaccination 
 
In the beginning of section 4 or 5, respondents were given written information phrased 
as follows: “We would like to inform you that HPV is a sexually transmitted virus 
which can cause condyloma in men and women, and cervical cancer in women. An 
effective HPV vaccine has been developed and is ready for use”. In case of the 
telephone interviews, the same information was read to the respondent over the phone. 
Respondents to the paper questionnaire were in connection with this information asked 
not to go back and alter any previous answers in the survey. For respondents to the web 
or telephone questionnaire, no such going back was possible. After the information, 
two questions on acceptability were posed; the first one asking “Would you want to be 
vaccinated against HPV if the vaccine is for free?”, and the second asking “Would you 
want to be vaccinated against HPV if the vaccine costs?”. (The cost of the vaccine was 
not pre-specified, as this was unknown when the questionnaire was designed.)  
 
Responses on acceptability were grouped into three different levels: 1) those 
unwilling/unsure if willing to vaccinate even if the vaccine was for free; used as 
reference category, 2) those willing to vaccinate if the vaccine was for free but 
unwilling/unsure if willing to vaccinate if the vaccine cost and 3) those willing to 
vaccinate and willing to pay for the vaccine if there was a cost. Note that the theoretical 
construct that we wished to investigate in Study IV is usually termed “acceptability” (or 
“acceptance”), whereas our actual study question measuring this construct used (the 
Swedish term for) “wanting to” or “willingness”. Therefore, the article refers to both 
terms, depending on context. 
 
4.6.5 Statistical analysis 
 
Study III  
 
Logistic regression model 
 
A binomial logistic regression model was used to examine correlates of high levels of 
HPV knowledge. Respondents were grouped in two groups; those with below median 
or median results on the HPV knowledge score (i.e. ≤4 points) – termed low knowledge 
– and those with above median score (i.e.>4 points) – termed high knowledge. The 
regression model was built through examining all potential correlates in a first full 
model. A backward stepwise approach was then taken, removing variables with non-
significant categorical effects whose removal did not affect the confidence intervals of 
other variables by more than 10%. This approach was repeated until only significant 
variables remained.  
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The prevalent odds ratios (OR) with 95% confidence intervals from the regression 
analyses are presented together with p-values for each categorical effect in the model, 






Since the overall response rate among young adults was only around 55%, it was 
apparent that some form of non-response analysis was appropriate. We opted to 
construct so-called response homogeneity groups (RHG), by a method previously 
described (152). This method tries, as accurately as possible, to describe the unknown 
response mechanism of the sample. Since data from Statistics Sweden were gathered 
for the entire study sample, it was possible to calculate a survey response rate according 
to a number of demographic characteristics. To determine the main factors predicting 
survey non-response, these socio-demographic variables were entered simultaneously 
into a logistic regression model using non-response to the survey as the outcome. In 
this analysis; the main factors correlated to non-response was gender, education level, 
birth country of the respondent’s mother, and presence of social welfare grant in the 
family. These factors were used to construct the RHG:s through the following 
approach. 
 
Initially, a matrix was set up where all subjects in the sample were classified according 
to their different combinations of the identified main non-response factors (for 
example: gender=male, education level=high school, birth country of mother=Sweden, 
social welfare grant =no). This classified all subjects (whether respondents or not) into 
16 possible combinations (here called groups) of these factors. Subsequently, the 
proportions of acceptability were retrieved for the respondents in each group and 
entered into the matrix, to represent the acceptability for all members in that group (i.e. 
also the non-respondents). A total proportion of willingness to vaccinate was then 
weighted together from all the groups, according to which relative representation that 
particular group had in the total original study sample (e.g. if group 1 had 12% 
representation in the original study sample, it would now be allotted 12% weight in the 
overall summation).  
 
In effect, this simulates what the overall acceptability proportions could have been, if 
all subjects in each group had answered to the questionnaire (instead of just the 
respondents). Thus, it corrects the underrepresentation in response of certain socio-
demographic groups in the actual study sample obtained, compared to the original 
sample. In so doing, one critical assumption is made: that people within the same 
(socio-demographical) group answer more similarly to each other than to members of 
another group, so that one can use the given answers among respondents in one group 
as proxies for answers among non-respondents in that group. Effectively, it is assumed 
that data is missing at random within the sample subgroups. However, such an 
assumption is not necessarily unreasonable, and usually presents a significant 
improvement over more naïve models that assume data are missing at random 
throughout the entire study population (152).  
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Note that the only item in the article adjusted for non-response is these proportions of 
acceptability presented in Table 2, all other frequencies and proportions are observed. 
 
Logistic regression model 
 
We used multivariate multinomial logistic regression to examine factors that may be 
associated with acceptability of HPV vaccine, because this outcome had three levels. 
The model included variables obtained from the questionnaire, and in certain cases, 
from the socio-demographic data obtained from Statistics Sweden. To test whether 
being female or male influenced the effect of the explanatory variables on acceptability 
of HPV vaccination, models with interaction terms between gender and each of the 
other explanatory variables were fitted. Since only few interaction effects were 
detected, the correlates are presented with the genders combined, with the interacting 
variables reported also separately. 
 
In order to examine potential correlates concerning sexual habits that applied to only 
sexually active respondents, a subgroup analysis among everyone excluding those who 
stated they had never had sex was conducted.  
 
To be able to present results regardless of univariate significance, the potential 
correlates were simultaneously entered into the models without further selection 
criteria. A p-value of <0.05 was considered statistically significant (although most of 
the p-values obtained in the analysis were much smaller). All prevalent OR:s in the 





5.1 STUDY I 
 
5.1.1 Characteristics of the study participants 
515 women with cancer in situ (CIS) and 315 women with squamous cervical cancer 
(SCC) were included, along with their matched control women. The median age at 
diagnosis was 33 years in the CIS group and 40 years in the SCC group. The median 
study time was 5 years for the CIS group and 7 years for the SCC group, with the last 
smear on average 0.6 years before diagnosis of CIS and around 2 years before 
diagnosis of SCC. Although the absolute number of smears varied significantly 
between women, the median number of smears was 2 per woman in all study groups.  
 
5.1.2 HPV prevalence 
HPV positivity in the first smear was three times as common in CIS and SCC cases 
compared to control women. Most of the HPV infections detected in the pre-diagnostic 
smears from cases and controls were due to HPV16/18 (35% in CIS cases and 44% in 
SCC cases). The prevalence increased from the first to last smear in cases but not in 
controls. Being positive for multiple HPV type categories (e.g. both HR and LR or 
16/18 and non-16/18) was quite rare in the study – around 11-16% of CIS cases, 6-9% 
of SCC cases and a few percentage units among the control women. 
 
 
Figure 1. HPV16/18 prevalence in cases and controls in CIS (left) and SCC (right). 
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In an alternate comparison, complimenting the perspective of HPV-positivity in 
first/last smear; we investigated HPV-status in a continuum of smears taken from ten 
years before diagnosis and up until point of diagnosis. The probability of HPV16/18-
positivity, and non-16/18-HR-HPV positivity was increased throughout ten years 
before diagnosis in cases compared to controls. However, the probability of being 
positive for LR-HPV was very similar in cases and controls over time before diagnosis. 
 
5.1.3 Risk associated with different HPV types 
The largest relative risk associations were seen for the HPV16/18-category, whether 
comparing to all other women, or just HPV-negative women. Further, the relative risks 
for CIS and SCC, respectively, were greater if HPV16/18 was found in the last smear 
than in the first. The same was seen for the non-16/18-HR HPV types, although the 
relative risks were not of the same magnitude as for 16/18.  
 
Due to a lack of power, we could not obtain single-type-specific risks for HPV16 and 
HPV18 separately when assessing CIS and SCC as separate outcomes. Therefore, in an 
exploratory analysis these outcomes were combined (effectively replicating a CIN3+ 
outcome).  
 
In the first smear, both HPV16 and HPV18-positivity was associated with a relative 
risk of around 11-12 compared to HPV-negative women. However, HPV16 showed a 
strong risk increase over time to a RR of 41 (95%CI 23-76), whereas the risk associated 
with HVP18 positivity increased only moderately over time to reach a RR of 16 
(95%CI 6-43). 
 
5.1.4 Risk associated with HPV16 persistence  
Just over a third of both CIS and SCC case women were persistent for the same HPV 
type in the first and second consecutive smears, compared to a mere 4% of the controls. 
The main persistent type was HPV16, followed by HPV18, 31, 33 and 52. Power was 
only sufficient for HPV16 in a separate regression analysis.  
 
This risk analysis showed a clear gradient of risk associated with HPV16, even though 
the low precision meant wide confidence intervals. Transience of HPV16-infection was 
not associated with any clear risk increase for either CIS or SCC, whereas having 
acquired an infection in the second smear was associated with an increased risk for 
particularly CIS, but also SCC.  
 
Persistence in the first two smears was associated with almost 20-fold increased risks 
for both CIS and SCC. The exposure status for cases and controls in this analysis is 
given in the table below. Many cases, but few controls were exposed to HPV 
persistence, yielding the high OR for +/+. Furthermore, since the analysis was 



















-/- 218 138 14 -/- 138 89 11 
+/- 11 11 9 +/- 5 10 10 
-/+ 8 32 30 -/+ 8 18 17 
+/+ 4 60 60 +/+ 4 38 36 
Total 241 241  Total 155 155  
 




Attributable risk proportions 
 
The following attributable risk proportions were calculated for the different HRHPV 
categories, according to the main effects model described above. 
 
 
CIS HPV16/18 Non-16/18 HRHPV 
First smear 29% (24-34%) 20% (15-25%) 
Last smear 49% (44-53%) 34% (29-39%) 
 
SCC HPV16/18 Non-16/18 HRHPV 
First smear 41% (35-47%) 10% (4-16%) 
Last smear 47% (41-53%) 19% (13-25%) 
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Additional data on sensitivity analyses according to histological re-review 
 
Graphs illustrating how the estimated OR’s are affected by the inclusion, or exclusion, 
of cases where the in-situ cases where downgraded from CIS (CIN3) to CIN2 in the 
histological re-review. As can be seen, the results in different classifications of disease 
(original versus revised) remained unchanged, although precision was low for assessing 
CIN2 risk-sets separately (also shown) conferring some variation in the point estimates. 
 
Analysis in first smear 
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Additional data on proportion of HPV-negative cases 
 
Proportion of HPV-negative smears from case women by latency between last smear 
and diagnosis, in CIS (“In-situ”) and SCC (“Invasive”). This proportion steadily 
decreases as time to CIS diagnosis draws near, although in SCC, the proportion was 
more stable. In case women whose last smear was less than 2 years before diagnosis, 
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5.2 STUDY II 
 
5.2.1 Characteristics of the study participants 
In total, Study II included 621 women with CIS, 457 women with SCC; and their 
matched controls. The median number of smears was similar, likewise the total range, 
although Table 1 in this study specifies inter-quartile range. Ages at diagnosis were 
similar to Study 1, as was study time although it was a little longer in both CIS and 
SCC. We here also describe the density of smears over 20 years before diagnosis, 
where it is apparent that cases and controls had the same amount of smears except for 
the last year before diagnosis. 
 
 
5.2.2 HPV prevalence 
The overall HPV positivity was 65% in smears from CIS cases, and in 55% of SCC 
cases, the majority of which were due to HPV16. 12-15% of control women’s smears 
were HPV-positive, of which 3-4% was due to HPV16. (Please note that these 
proportions are not stratified on first/last smear, as was done in Study I.) 
 
5.2.3 HPV16 viral load dynamics  
From Figure 1, it is apparent that average HPV16 viral loads increased continuously in 
HPV16-positive smears taken from 10 years before, and up until time of diagnosis of 
CIS. The strongest surge was seen in the last year before diagnosis. In SCC, there was 
more of a plateau phase in contrast, but here also a surge was seen especially during the 
last two years before diagnosis. 
 
Figure 2. HPV16 viral load in copies/microliter over time to diagnosis, in cases of CIS 
(left) and SCC (right). Case-case comparison. 
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Since a strong period effect was found for viral load in CIS (see Methods), no raw viral 
load data (i.e. without taking period into account) are presented, as such results would 
be difficult to interpret. Therefore, Figure 1 shows viral load levels stratified for 
calendar period in case women with CIS, or SCC, respectively. For CIS cases, women 
who were followed for ten years in the earliest period had the highest loads at 
diagnosis, whereas women who were followed for ten years in the last periods had the 
lowest. A similar trend was visible for SCC cases but this was not statistically 
significant. 
 
We further observed that women later diagnosed with CIS or SCC initially had 
unexpectedly low viral loads, especially in the later calendar periods. In SCC, this was 
quite pronounced from ten years to about four years before diagnosis. The late surge, 
however, resulted in high average viral loads at diagnosis in both groups. 
 
 
5.2.4 Risk associated with HPV16 viral load 
 
Initially, imputation models were constructed using tertiles of HPV16 viral load levels 
as cut-offs for categorization of exposure, as described above.  
 
 
Figure 3. Relative risk (RR) for individual tertiles of HPV16 viral load in CIS, over 
time before diagnosis in years. The horizontal line at RR=1 is the reference level of 
HPV16-negative. 
 
In the imputation model for CIS, the medium and highest tertiles aligned in risk 
throughout ten years before diagnosis. To increase precision, these were therefore 
collapsed into one. (See Supplementary Data for further information on this.) In the 
final CIS model; being HPV16-positive of the lowest viral load tertile was associated 
with a constant 10-fold increased risk throughout ten years before diagnosis, compared 
to HPV16-negative women. Initially, the risk associated with medium/high HPV16 
viral load was similar to this.  
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However, at around seven years before diagnosis, there was a risk separation between 
the lowest and the medium/high category, so that women with a medium/high HPV16 
viral load eventually had a relative risk of around 40 during the last year before 
diagnosis. This risk separation, although low in precision, was robust in sensitivity 
analyses. 
 
Overall HPV16-positivity conferred a risk profile similar to that of the low viral load 
category, until the last 2-3 years before diagnosis where a more intermediate position 
between the two was assumed. High-risk HPV positivity was similar to HPV16-
positivity over this time.  
 
In the SCC initial model, the low and medium tertiles were similar and thus were 




Figure 4. Relative risk (RR) for individual tertiles of HPV16 viral load in SCC, over 
time before diagnosis in years. The horizontal line at RR=1 is the reference level of 
HPV16-negative. 
 
Between ten to three years before diagnosis, both low/medium and high viral load was 
similar in terms of risk, but then a risk separation similar to that in CIS occurred as 
well. So, although for the majority of the study time the risk for SCC appeared mainly 
associated with HPV16-positivity of any viral load level, from around 3-4 years before 
diagnosis the high category did appear to confer a significantly increased risk. 
Ultimately, this risk increase ended at around 70-fold, in contrast to the 20-fold risk 
associated with the low/medium category, compared to HPV16-negative women. 
Again, this risk separation was robust in sensitivity analyses, although somewhat less 
dramatic when considering histologically re-confirmed cases only.  
 
HPV16-positivity and HR-HPV-positivity conferred much the same risk profile as the 




5.3 STUDY III 
 
5.3.1 Characteristics of the study samples 
• Parents 
The median age of parents was 44 years. Almost equal numbers answered through the 
web questionnaire (42%) and paper version (39%). Most were born in Sweden (87%) 
and the majority lived in rural or small town areas. 76% were either married or had a 
partner, and the mean number of children per household was 2.2. 38% had higher 
education than high school and 87% were gainfully employed.  
 
• Young adults 
The median age was 24 for women and 23 for men. Most chose the web-based 
questionnaire as response method. More men than women responded via telephone 
interview. Most respondents were born in Sweden (89-90%) and were non-married (90-
96%). Two thirds of the respondents lived outside of Sweden’s largest cities. The 
degree of highest education in the sample varied, as expected given the age 
demographic of the group. 
 
5.3.2 Response rates 
• Parents 
The response rate was 70% among mothers and 69% among fathers. Mothers 
accounted for 58% of the respondents. 
 
• Young adults 
The response rate among women was 55% and among men 43%. Women accounted 
for 84% of the respondents. 
 
5.3.3 Awareness and knowledge of HPV 
Since awareness of cervical cancer and condyloma was high, but awareness of HPV 
was low; understanding of the causal link between the two was naturally limited. Even 
among those that had heard of HPV, how many were aware of the link between HPV 
and cervical cancer varied strongly within the respondent groups. Slightly more 
concurrent between groups, but even lower absolutely speaking, was the knowledge 
that HPV caused condyloma. Female parents generally were the most knowledgeable, 
and young men the least. Interestingly, there was one case where this did not apply; 
namely the question on whether HPV can cause other cancers. This question clearly 
was the most difficult for respondents to answer, with around 64-69% of respondents in 
all groups being uncertain.  
 
There was a contrast between the item on whether HPV is sexually transmitted, which a 
large majority of respondents stated “Yes” to, and the item on whether men can become 
infected with HPV, to which 10 percentage units fewer respondents said “Yes”.  
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In combination with the fact that almost all respondents stated that women could 
become infected with HPV, this may point to some of the complexities involved in 
conceptualizing HPV as an STI when it is still mainly associated with cervical cancer in 
women. 
 
5.3.4 Correlates to correct knowledge of HPV 
It should be said that many potential correlates were assessed to establish whether there 
was a relation with the outcome HPV knowledge (for the young adults all variables 
listed in Table 3 in Study IV). However, (surprisingly) few correlates came up stable. 
In young adults, no questions on sexual habits showed significant effect in the model 
build. Classic demographic factors were the main correlates for high knowledge; 
gender, income, education and country of origin. In young adults, a (paradoxical) 
correlation between low income and high knowledge was seen, but this may be due to 
residual confounding, from not having entirely updated information on educational 
degree in this mobile young cohort. 
 
A note should be made to the significance of the response method, where those that 
responded through the internet showed higher knowledge. As discussed further in 
article IV (see the Discussion section in that paper), respondents were not randomized 
to different response methods, but self-selected whether to answer online or not.  
 
 
5.3.5 Sensitivity analysis 
Although not included in the paper due to the small changes in results, and the brief 
format, the same non-response analysis carried out in Study IV (see Methods) was 
carried out also for this study for the young adults group. The proportions of awareness 
for cervical cancer and condyloma shifted somewhat downwards when under-
represented respondent groups were brought in. However, HPV awareness remained 
very stable. 
 











   
    Heard of HPV Yes 19,9 19,2 12,6 12,2 
  No 80,1 80,8 87,4 87,8 
    
    Heard of cervical 
cancer Yes 91,4 90,4 69,7 68,4 
  No 8,6 9,6 30,3 31,6 
    
    Heard of condyloma Yes 91,4 89,3 84,7 82,5 
  No 8,6 10,7 15,3 17,5 
 
Table. Adjusted and non-adjusted proportions of awareness of HPV, condyloma and 
cervical cancer. 
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5.4 STUDY IV 
 
5.4.1 Characteristics of the study sample 
As the same sample of young adults was used, please see above under Study III. 
 
5.4.2 Response rates 
As stated above, the response rate in the young adults was significantly lower than in 
the parents’ group, 55% overall versus 75%. Therefore, in this study a more formal 
non-response analysis was performed. The lowest response rates were seen among men 
in general, and – among both women and men – those respondents born outside the 
Nordic area, where birth country was unknown, and among those on social welfare 
grants.  
 
5.4.3 Acceptability of HPV vaccination 
The overall response to the main study question is given in the table below. 
 
 Unwilling/unsure if 
willing even if for free 
Willing to vaccinate but 
only if for free 
Willing to vaccinate 
even if it cost 
Women 25% 34% 41% 
Men 32% 37% 31% 
 
Men who reported only homosexual contacts had very similar levels of acceptability 
compared to men who reported only heterosexual contacts. Men who reported bisexual 
contacts appeared to have higher interest than other men to vaccinate whether if for free 
or not, but this did not reach statistical significance (p=0.3). 
 
When adjusting these proportions for the main correlates of non-response, they 
remained virtually unchanged. Thus, the factors predicting non-response did not appear 
to predict acceptability to the same degree, meaning that when under-represented 
response groups were allotted more weight in the analysis, our results remained largely 
unchanged. (Indeed, as seen in Table 3, the factors correlated to non-response were not 
the most correlated to acceptability.)  
 
5.4.4 Correlates to acceptability 
In our analysis of correlates to willingness to vaccinate, we found several significant 
correlates, although most estimates were moderate, with OR:s of around 1.5-1.7 at the 
highest (indicating a 50-70% increased willingness relative to the reference level, i.e. 
those not willing to vaccinate even if for free). Some of the largest estimates were seen 
for bisexual respondents, and for those who perceived themselves to be at a fairly large 
or large risk for contracting an STI. The latter was also the strongest correlate to 
willingness to vaccinate even if it cost; with an OR of 2.00 (95% CI 1.6-2.6).  
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The chief correlates to lowest interest to vaccinate whether if for free or at a cost were, 
perhaps logically, related to non-belief in the efficacy of vaccination to prevent disease 
(OR for willingness to vaccinate even if it cost 0.3, 95% CI 0.2-0.4), and to a non-belief 
that vaccines are safe. Less expected was the finding that not having made one’s sexual 
debut was correlated to a decreased willingness of approximately the same size as non-
belief in the safety and efficacy of vaccines (OR for willingness to vaccinate only if for 
free 0.4, 95% CI 0.3-0.5 and OR for willingness to vaccinate even if it cost 0.4, 95% CI 
0.3-0.4). 
 
In the subgroup analysis among those that had made their sexual debut, several factors 
were correlated with an increased willingness to vaccinate: young age at sexual debut, 
having tried anal and/or oral sex, and having had an above median number of partners 
in the last year. For women, awareness of cervical screening, or participation in cervical 
screening, were not strong correlates to willingness to vaccinate. 
 
5.4.5 Perceptions of HPV vaccine and health behaviors 
Among both men and women, only around 13-15% believed they would be fully 
protected against condyloma after HPV vaccination. A large proportion (around 43%) 
was uncertain. Few women (6%) stated they might use fewer condoms after 
vaccination, and 80% stated a definite “No”. However, around 12% of men stated that 
could be the case and men were also more uncertain of whether they might have more 
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Although only few women (around 6%) believed they would be fully protected against 
cervical cancer after HPV vaccination, around the same amount of women believed 
they would not attend screening as often after vaccination. Among women who had not 
participated or heard of cervical screening before the study (i.e. the young women, see 
graph below), the uncertainty was widespread in comparison to the older women. 
 
 Figure 6. Proportions of response on cervical screening participation, stratified on 
age. 
 
The main concern about HPV vaccination in both genders, and the main factor to 
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We shall not cease from exploration  
And the end of all our exploring  
Will be to arrive where we started  






6.1 STUDY I: HPV TYPES AND HPV PERSISTENCE  
 
6.1.1 Main findings and interpretation 
Study I provides prospective evidence of the strong risk profile of current HPV vaccine 
types HPV16/18 in both CIS and SCC, and also shows that non-16/18 high-risk HPV 
types increase the risk for invasive squamous cervical cancer. Therefore, it is estimated 
that a vaccine covering the non-16/18 HRHPV types could confer an additional 20% 
protection against SCC. It further confirms that persistent infection with HPV16 
appears strongly linked to the risk for both CIS and SCC. These results support the use 
of persistent infection as an endpoint in HPV vaccine studies, a strategy which is not 
fully accepted. 
 
6.1.2 Methodological considerations and validity 
The strengths of Study I and II revolve around the quality of epidemiological, 
molecular and biostatistical expertise involved. Much time was spent on the design of 
the study and recruitment of county laboratories willing to participate, and further 
substantial efforts were dedicated to gathering smears for analysis and histological 
specimens for review. For a prospective study, the sample of invasive cancers is, to our 
knowledge, uniquely large. Subsequent large-scale efforts were devoted to DNA-
extract and completely HPV type the smears using validated methods, and further to 
analyze and interpret the data. The laboratory analysis was accredited as an HPV 
reference laboratory, with very high standards for procedures, and was blinded to case-
control status, and structures of risk-sets. This was done in order to disable the 
possibility of differential misclassification of exposure due to case-control status being 
known. Further, our pathologist was blinded as to whether the samples were originally 
coded as CIS or SCC. As such, the internal validity of our archival smear studies 
should be strong.  
 
We did not reach 100% HPV-positivity in our case smears, which can be a ground for 
criticism. In smears taken close before diagnosis, we reached around 80% HPV 
positivity (see article I) which we conclude is the overall sensitivity of our archival 
smear method. We do not believe that 20% of tumors in our study were not caused by 
HPV, but instead, that the reduced HPV detection can be explained by several different 
factors. Firstly, the ubiquitously cited 99.7% attributable fraction to HPV was reached 
in tumor samples after subjecting them to three different PCR:s (153), whereas we only 
used one. Secondly, in a recent meta-analysis of invasive cancer cases, the overall HPV 
prevalence found was not 100%, but 89%, which is more similar to ours (154).  
 
Moreover, we examined HPV prevalence in archival pre-diagnostic smears, rather than 
the actual diagnostic tissue biopsy. As such, the smear may be prone to sampling error, 
if not enough infected cells were picked up to trigger high-risk HPV detection. 
However, likely this reduced sensitivity could be non-differentially distributed between 
cases and controls, which would bias our results and attributable risk proportions 
towards the null, rather than inflate the risk associations (26). 
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In connection with this, ideally we should have HPV-typed the tumors belonging to the 
case women. This would have allowed us to study type concurrency in the smear and 
the tumors, and perform a closer investigation of the HPV-negative smears. However, 
to also type tumors was beyond the scientific scope of the study, as the original aim 
was to investigate screening tests over several years before diagnosis – i.e. where the 
future tumor type by necessity is unknown. 
 
The sampling frame being the screening program in Sweden entailed that the results 
should be generalizable to a large part of the (Swedish) female population, and 
although it should be noted that cases and controls were matched on some basic 
criteria, these are unlikely to bias the findings much. Ultimately, we believe we have 
good generalizability in these studies as we have no reason to suppose that the overall 
risk profile of HPV infections, and relative contributions of HPV16 and other HR 
types, would be substantially different in non-screened groups. Further, although non-
participation is a reason for cervical cancer in Sweden and needs to be improved, in the 
study of screening tests, sampling screening participants does not constitute selection 
bias. We did select women with a first normal smear, but this did not limit the study 
base much (see Methods), although we recognize that women with later disease may 
have been disproportionately present in that removed group. However, this strategy 
enabled us to study a more homogenous group which was deemed important in terms 
of internal validity, and enable the study of the progression from normal smear to 
cancer.  
 
We did not have data on potential confounders such as oral contraceptive use, or 
smoking, as described in Introduction. However, compared to the large magnitude of 
the HPV effect size, these effect sizes have been shown to be modest, with ORs/RRs of 
around 2-3. Although of etiological interest, we therefore do not believe that they have 
heavily confounded our results (26). Another limitation to these studies include the 
large variation in the number of smears between women, and before these studies were 
launched, it was a point of discussion whether to also match on number of smears, to 
ensure comparable power of comparisons between case women and controls. 
Ultimately, it was felt that matching on number of smears would have run the risk of 
introducing bias into the study. This since the reasons for why case women and controls 
have different numbers of smears throughout life might correlate to HPV exposure 
status, and that forcing the smear density to coordinate could constitute over-matching 
(155). However, since the resulting median smear density was only around two smears 
per woman, it was not possible to evaluate more sophisticated measurements of 
persistence than HPV16-positivity in the first and second consecutive smears.  
 
6.1.3 Comparison to other studies 
The strong carcinogenic effect of HPV16 is now well-established, and some large 
studies have advocated the use of separate typing for HPV16/18 alone to risk stratify 
women in HPV-based screening (156). However, it has been shown that HPV31 and 33 
are also associated with a high risk, and that other high-risk types are associated with 
differing risk for CIN2+ (157). We confirm this finding for our non16/18 HR HPV 
group, although their relative contribution was greater to CIS than SCC.  
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In terms of prospective risks for non16/18-HR HPV types in HPV-based screening, 
further follow-up from screening studies is needed to inform practice. 
 
A recent study estimated the relative contributions (RC) of the nine types included in 
the coming nonavalent vaccine (HPV6, 11, 16, 18, 31, 33, 45, 52 and 58) based on data 
on HPV typing in invasive cancer tumors from 38 countries. By a proportional 
weighting method, and assuming 100% of cervical cancers were HPV-related, it was 
calculated that the RC of the nine vaccine types was close to 90% (158). Of these, the 
five non16/18 high risk types accounted for around 19%, which is in line with our 
attributable risk proportion of 19% for non16/18 HR HPV in the last smear before 
diagnosis.   
 
6.1.4 Implications for continued research and practice 
It appears crucial to continue the long-term follow-up of the risk associated with HPV 
types in cervical screening. Apart from long-term follow-up of the initial randomized 
HPV-based screening studies, also the typing of incident cervical CIN and manifest 
cervical tumors should be prioritized, to determine which HPV types are causing 
lesions and if any tumors might be HPV-negative. To establish a correct baseline 
containing both vaccination status and tumor status will serve as a valuable comparison 
for future studies of HPV vaccine effects on population-level, and inform decision 
making as well as detect potential vaccine failures. Such continued monitoring of 
potential cross-protection and/or type-replacement appears essential. 
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6.2 STUDY II – HPV16 VIRAL LOAD  
 
6.2.1 Main findings and interpretation 
In Study II, we demonstrate that the dynamics of HPV16 viral load appear to lend 
important clues to the understanding of HPV infectious natural history, but that these 
dynamics are also highly complex. The use of HPV16 viral load in HPV-based cervical 
screening may therefore be challenging and would require a diligent clinical evaluation. 
Furthermore, HPV16 viral loads were unexpectedly low in invasive cancer, which 
should be considered when weighing sensitivity against specificity in HPV-based 
screening.  
 
6.2.2 Methodological considerations and validity 
In terms of strengths and weaknesses of study design, the same principles as in Study I 
apply here also. In addition, the sample size was larger in this study, which was 
necessary to investigate the more complex outcome of quantitative infection. We used a 
type-specific realtime-PCR method for measuring viral load, which is methodologically 
more advanced than semi-quantitative measures (159).  
 
Compared to Study I and qualitative infection, it was infinitely more challenging to 
comprehensively assess this viral load data. Upon close examination, it was evident that 
great care was needed in the statistical analysis. We therefore systematically assessed 
the data for potential error resulting from factors such as analysis person, date, or 
calendar period. When such tendencies were found, we adjusted for it as carefully as 
we could, resulting in several layers of adjustment. The relatively low density of smears 
limited the precision of Study II, since the more longitudinal smear information there is, 
the more the imputation model is informed. Taken together with the uncertainty added 
by the imputation procedure, the low density entailed that precision overall was low for 
the viral load risk analysis. As shown, the precision is significantly better when 
estimating risk according to qualitative infection with HPV16, or all high-risk HPV.  
 
Even though our imputation is relatively imprecise, and is subject to additional layers 
of adjustment (i.e. for assay drift and calendar period effect) it still yields results for 
CIS comparable to other research, and we thus consider the validity for our SCC risk 
prediction to also be reliable. 
 
The calendar period effect was the most dominating in our data, yet the most difficult to 
comprehensively explain. We assessed several different factors (time trends in HPV16 
prevalence, histological re-review results, and systematic errors as described above) but 
could not derive any definite explanation from these. Also, whereas some multiple 
infections were present, these were not nearly common enough to explain the very 
strong calendar period effect, resulting in a viral load difference of one magnitude in 
the 1980’s compared to the late 1990’s and beginning of the 2000’s. A potential 
explanation however, although not formally possible for us to evaluate, could be that 
cervical screening has improved and now detects smaller lesions, potentially of a lower 
viral load at diagnosis, than in the 1980’s.  
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In terms of generalizability we believe our conclusion of the complexity of using 
HPV16 viral load should apply also in unscreened women, compared to the stability of 
using qualitative infection as a risk marker. However, as we discuss in the article, our 
decision to include only women with a first normal smear may have affected the viral 
load results in especially SCC. Thus, we acknowledge that viral loads in women 
screened with a first abnormal smear may exhibit different characteristics and a 
qualitatively different viral load kinetic curve over time before diagnosis. 
 
6.2.3 Comparison to other studies 
Some interesting complementary findings have been made recently in the viral load 
field. A case-cohort study has been carried out in Belgium, with quantitation of all 
single-type HPV infections in a large population-based material. In line with previous 
research, a strong risk association between viral load and risk of CIN3+ was 
demonstrated. Additional data on viral load kinetics showed that in HPV infections 
leading to CIN3+, viral load increased almost linearly each given day (160). This is 
well in line with our increasing curve in CIS/CIN3, although the number of cases of 
invasive cancer in the study was nigh on non-existent (n=7), precluding direct 
comparisons to invasive disease. In India, similar results were reported very recently, 
again confirming the large risk association between viral load and CIN3+ (161). As in 
the Belgian study, the small number of invasive cancer cases (n=16) precludes closer 
comparison, although it can be noted that 12 of these cases were found in the highest 
viral load category. Again, the minute number of invasive cancers accrued in these 
studies illustrates the power of our nested design. 
 
The Indian study also reasons around the trade-off between sensitivity and specificity 
as related to viral load in their study. If their Hybrid Capture II cutoff had been 
increased to 2 relative light units (RLU) instead of 1, an additional 185 women with 
normal or CIN1 histology would have tested HPV-negative. However, one woman with 
CIN2 and one with cancer would have been missed. However, if they had reduced their 
RLU-limit to 0.5, it was calculated that only one additional CIN2 would have been 
detected, at the cost of 747 additional women who would have tested positive despite 
subsequent normal or CIN1 histologies (161). 
 
6.2.4 Implications for continued research and practice 
What does viral load actually stand for? The a priori hypothesis in this study very much 
was that HPV16 viral load drove progression to disease, whether CIS or SCC. As a 
seminal study on HPV16 viral load in CIS had previously demonstrated loads to be 
consistently high (79), we hypothesized that viral loads in invasive cancer would be 
even higher. A continuation of the upwards curve. However, as can be seen from Study 
II; this hypothesis was directly contradicted by our data. Viral loads in SCC exhibited a 
plateau phase, beginning at a very low level that was quite unexpected. Both disease 
groups showed a strong surge towards the end. This could represent a final disease-
inducing effect of increasing viral load, or increasing viral load reflecting a larger, 
underlying expanding clone of HPV-infected malignant cells about to be diagnosed 
through cytology. It is difficult to determine which explanation is correct.  
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Whether viral load is the direct cause of HPV16-induced disease, or more of a risk 
marker, would be less central for screening inference so long as it stably served to 
single out women at highest risk (or those at lowest). Since the results for CIS were so 
strong, it was initially thought that, in the context of HPV-based screening, HPV16 
viral load might indeed serve as a primary screening test, determining which women 
were at highest risk of cervical disease. Thus, it was foreseen that HPV16 viral load 
might dictate what follow-up could be appropriate for different women (155).  
 
However, the picture from our Study II emerges more complicated than that. Due to the 
low precision of the study, it is difficult to draw detailed inference regarding exact 
effect sizes of the risk associated with viral load. However, it is still possible to 
interpret the overall implications as a result of the risk associations.  
 
The differing thresholds for the risk separation in CIS and SCC means that, in a 
screening situation, it would be challenging to a) define what “high” viral load actually 
should be and b) risk stratify a woman with, e.g., a medium tertile HPV16 viral load. If 
it were close to time of diagnosis, she would be in the highest risk group for CIS, 
compared to HPV16-negative (and HPV-negative) women. However, she would not be 
in the highest risk group for SCC, whereas she would still be in a risk group for SCC 
compared to HPV16-negative women. Furthermore, the risk profile for CIS and SCC 
was dependent on time scale of disease development, since the risk separation occurred 
only late in SCC. Therefore, for a large part of CIS or SCC disease development, 
women are at similar risk regardless of viral load status.  
 
Compared to instead triaging women according to the stable risk exhibited by being 
HPV16-positive, of any viral load level, at any point during ten years before diagnosis, 
the wide-spread use of HPV16 viral load in screening is not supported by this study. 
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6.3 STUDY III – AWARENESS AND KNOWLEDGE OF HPV 
 
6.3.1 Main findings and interpretation 
Pre-large scale HPV vaccination campaigns, awareness of HPV-related diseases was 
high but awareness of their causal factor HPV was low. Most respondents could 
correctly identify that women could be infected with HPV but whether men could be 
infected with HPV was not as clear to respondents, especially not among young men 
themselves. This should be corrected in vaccination campaigns, to promote better HPV 
knowledge. This would naturally be especially important if male vaccination were ever 
to be introduced. 
 
The obvious limitation to this study is that it took place at such an early stage of HPV 
vaccination, and that the outcomes may be different today. It should therefore first be 
clarified that the intent was to serve as a baseline study. It was designed to investigate 
the degree of HPV awareness and knowledge before the introduction of large-scale 
vaccination campaigns, to help inform content educational messages and campaigns. 
Although the data are thus not totally current, we still believe the study holds several 
merits. These will be discussed here, along with an assessment of the relation of our 
results to today’s situation. 
 
6.3.2 Methodological considerations and validity 
We note that the questionnaire used in both this study and study IV was not validated 
formally, a feature that is indeed frequently lacking in the field (62) although some 
examples are available (162). However, our questionnaire was constructed by 
researchers with significant experience from survey research, and processed through 
the Questionnaire Advisory Group at MEB, a group with long experience in survey 
design. The questionnaire was also pre-tested for question flow and logic, in a small 
sample of eligible adults (n=50) before being sent out, with a good result.  
 
Regarding the survey design, the questionnaire may be critiqued for risking prompting 
response bias in the HPV knowledge section, since the correct answer to all questions 
was “yes”. In a recent study which validated a measure of HPV knowledge, answers 
were instead varied between true and false (62). Nevertheless, in this study we did 
obtain significant variations in response patterns intra- and inter-respondent groups, and 
many chose the alternative “Don’t know” instead of saying “Yes” to all questions.  
 
In the questionnaire, it could furthermore have been good to have information on other 
factors of interest such as alcohol use, tobacco use, oral contraceptive use, and previous 
history of HPV-related disease, to correlate to knowledge and other outcomes. 
However, when designing the questionnaire it was felt that a previous study had charted 
several of these factors on a population level (41), and that the focus of the current 
survey should be more on awareness and knowledge of HPV (and acceptability).  
 
Because few factors were strongly associated with having a high HPV knowledge score 
(as opposed to acceptability in Study IV), we opted for a backwards stepwise selection 
model to remove the many redundant variables.  
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We did however not formally assess model fit in Study III (or IV) and our discussion 
on this is perhaps a bit limited, given the significance of this factor (163). However, we 
still believe we reach an effective model for showing the main factors of relevance to 
the outcome. 
 
Compared to many other surveys in selected samples such as university students or 
women attending dysplasia clinics, Study III and IV used the Swedish Total Population 
Register as a sampling frame. As such, the generalizability should be strong. However, 
whereas the response rate in parents was good (70%), the response rates in the young 
adults were lower, particularly among men (44%). Therefore, it should be 
acknowledged that we are not sure of the representativeness of the sample to the source 
population. However, in our non-response analysis the adjusted frequencies for 
awareness of HPV and related diseases did not change substantially, indicating that the 
bias from non-response may be limited. 
 
6.3.3 Comparison to other studies 
Although the literature on HPV awareness and knowledge has now increased 
exponentially, the wide-spread continued use of selected samples and diverging 
geographical settings means comparison is challenging, since recent large-scale 
population-based studies are still sparse. As a brief example, we show low awareness of 
HPV in 2007, with only 13-23% of Swedish young men and women, and 17-29% of 
fathers and mothers having heard of the virus, respectively. In a recent study among 
patients at a dermatological outpatient clinic in Germany – i.e. a quite selected material 
– still, only 40% of respondents had heard of HPV despite a median age of 44 in those 
attending. Of those HPV-aware, only around 66% stated that HPV causes genital warts, 
and only around 58% that it causes cervical cancer (164). Although the knowledge of 
condyloma was improved from our result of 40-56%, the understanding of cervical 
cancer was actually lower than our result of 56-82%, despite the selected nature of their 
sample, and several years’ difference in time. This aspect is further emphasized by 
findings from a recent qualitative Swedish study among young HPV vaccinated 
women, which show a continued lack of understanding of the relation between sexual 
transmission, HPV and cervical cancer (165). 
 
Similarly, in a recent population-based validation study, the item on whether HPV 
vaccine protects against condyloma (there termed genital warts) was still very difficult 
to answer correctly for respondents from three different countries (USA, the UK and 
Australia), along with items on whether it is true that HPV needs no treatment, and that 
no HPV means cancer risk is low (62). The correlation between self-rated HPV 
knowledge and objectively measured such was low, which emphasizes the need for 
objective assessment for inference regarding increased knowledge. The validated 
question set appears promising and could likely be valuable for the standardization of 
research across countries. However, this publication contained no actual data on 




6.3.4 Implications for continued research and practice 
In this study, we assessed awareness and knowledge of HPV before large-scale 
implementation of HPV vaccination in Sweden. The vaccine had been introduced to the 
market in late 2006, and some advertising had taken place, above all for the subsidized 
group girls aged 13-17 years. In late 2008, the Nobel Prize was awarded to Harald zur 
Hausen for the discovery of HPV, which may have helped to raise awareness somewhat 
after the survey was conducted. However, it took two factors in Sweden to really 
increase awareness of HPV and HPV vaccination: the drawn-out, complicated vaccine 
tender process which included two appeals of the national purchase, and the 
introduction of school vaccination (166).  
 
Both of these occurred after our data collection, and likely the results today, if a follow-
up study were to be performed, would show higher awareness. Since a major discussion 
in the tender process was which value would be allotted to protection against 
condyloma (167), it is also conceivable that the past debate has helped understanding of 
the causal link between HPV and condyloma. Understanding of HPV’s contribution to 
other cancer forms may also have started to trickle into the population as the subject of 
male vaccination has started to be discussed, but it is unclear to what extent. 
 
However, as described above under 6.3.3, the actual extent to which media attention 
and vaccination campaigns have altered the degree of, and correlates to, degree of 
accurate knowledge that we demonstrated, is unclear. For example, despite all the 
attention surrounding the tenders, the current advertising campaign from Stockholm 
County Council for the catch-up vaccination with the quadrivalent vaccine does not 
prominently feature that the actual vaccine purchased protects against condyloma,  
although this information is mentioned in sub-pages of the campaign web site (168).  It 
is further unclear how much (if at all) the relative difference between female and male 
parents, and female and male young adults, has improved. As such, follow-up studies 
of awareness and knowledge of HPV in the population would be of interest.  
 
In order to ensure equal access to vaccination, follow-up studies should also be 
performed to assess whether non-uptake of vaccination is correlated to poor 
understanding of the nature of the viral mechanisms involved. The current advertising 
campaign for vaccination against cervical cancer is focused entirely on girls/women. 
But if boys and men are ever to be included in vaccination, campaigns ensuring correct 
understanding of HPV transmission and disease in males would naturally be needed. 
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6.4 STUDY IV – ACCEPTABILITY OF HPV VACCINATION  
 
6.4.1 Main findings and interpretation 
Study IV shows that theoretical acceptability of HPV vaccination was relatively high 
among young adults in Sweden pre-large scale HPV vaccination campaigns – although 
until 2010 only few had chosen to get vaccinated, likely due to the high cost. We also 
show that information about the benefit of vaccination before sexual debut should be 
improved. The main concern about HPV vaccination was whether the vaccine could 
have any side effects. Few respondents stated health behaviors could change, but this 
needs further follow-up. 
 
6.4.2 Methodological considerations and validity 
Regarding survey design, although the questionnaire section on acceptability had not 
been formally validated, it was developed with great care as described above under 
Study III. For future surveys, it can be noted that there have now been some validation 
studies on HPV vaccine acceptability which could be of use (169). 
 
When we built our statistical model for acceptability, unlike in Study III; many factors 
actually correlated with the outcome. We wished to be as hypothesis-free as possible 
when building the model, since many other studies in the area select only few variables 
into the final model, without reporting all variables that were triaged. In the 
awareness/acceptability field, it is common to use forward selection procedures where 
the potential correlates are only assessed one by one in relation to the outcome, rather 
than with other potential correlates as well. We believe our method therefore holds 
advantages, although as in Study III, we could have more formally reasoned around, or 
assessed, model fit (163). 
 
We did not enter the HPV knowledge score into the regression model since “mere” 
HPV awareness was a clear correlate of increased willingness to vaccinate, whether for 
free or not, and we believed this was of higher priority to report. It would have been 
informative to have a variable in the questionnaire on past history of HPV-related 
disease, to see how this was correlated with acceptability of vaccination. However, it is 
quite possible that our variable on STI risk perception captures some of the individual’s 
previous STI history, including that of e.g. condyloma, meaning that we assessed some 
of this factor in any case.  
 
An individual who already had condyloma or a cervical lesion would likely have a 
reduced effectiveness against that HPV vaccine type and so, assessment of acceptance 
of prophylactic vaccination in that group might appear more of academic than policy-
based interest. However, it would have been interesting to know something of about 
potential acceptability in those already HPV-afflicted. This could have been important 
information for observational studies of vaccine effectiveness as a function of age at 
vaccination. A recent Swedish study found no HPV vaccine effectiveness against 
condyloma if above 22 when vaccinating, which could be explained if older women 
with higher risk for, or even prevalent, condyloma self-selected vaccination (100). 
Information on acceptability in this specific group could thus have been useful. 
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Gender was clearly a determinant of acceptability. Although the questionnaire specified 
that men could also gain benefit from protection against condyloma, the described 
protection against cervical cancer likely led to the high acceptance in women. It has 
been shown that messages on cervical cancer for female partners do not resonate 
among adult males or parents, but that more data on HPV-related disease in general 
should be incorporated in studies on male acceptability (119). This was also confirmed 
in a recent study on acceptability among boys age 16-18 years (115). Had the 
information mentioned potential protection against other cancers in males, we 
acknowledge that this might have increased the acceptance in men. However, at the 
time of questionnaire construction, claiming protection against cancers in males and 
sites other than cervical, would have been difficult to defend from an evidence-based 
perspective.  
 
Regarding the generalizability of findings, the potential for this is significantly 
strengthened due to the population-based nature of the survey. However, it is also 
limited due to the suboptimal response rates, again particularly among young men. 
Therefore, inference on generalizability should be carefully balanced. We believe we 
have strengthened the validity and generalization of findings since our non-response 
analysis, which used a standard method for examining survey non-response (152), did 
not identify any major bias in acceptability. 
 
6.4.3 Comparison to other studies 
Higher income was expectedly correlated to higher acceptability but we also found that 
a higher education was correlated to a decreased acceptability, a finding which mirrors 
that of our previous study in parents (111). Although the latter finding may appear 
counterintuitive, this was actually echoed in recent studies on HPV vaccine uptake in 
Canada and the USA, which have found lower uptake in children to parents with more 
education; girls attending private schools; and boys living in high-income households 
(170-172). Furthermore, an English study on non-uptake of HPV vaccination found that 
affluent parents were more likely to actively decline vaccination, whereas living in a 
deprived area was associated with passive non-response to offer of vaccination (173).  
 
However, in the recent Swedish study on effectiveness of HPV vaccination against 
condyloma, it was found that opportunistic HPV vaccination of females was actually 
much more common if parents had high education (OR = 15) (100, 174).  
 
Can we unite these findings? The tendency for higher education to correlate to negative 
attitudes might be more applicable in a school vaccination setting, where actively 
abstaining from the norm of vaccination might be easier for those with a high education 
(and, potentially, higher confidence in decision-making). Opportunistic, i.e. voluntary 
vaccination, although principally different, also requires active decision making, 
especially in settings where vaccination is not the norm (i.e. the low uptake in the 
Swedish catch-up program). Perhaps higher education confers more confidence to act, 
in either case? This remains speculative, and we acknowledge that this may be a sign 
that our acceptability results are not fully generalizable to actual population uptake.  
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Further studies on uptake are clearly called for, to investigate to what extent receipt of 
HPV vaccine is dictated by socioeconomic status, thereby creating social inequity. It 
would also be of great interest to, in detail, examine non-acceptants of vaccination, 
although recruiting to such a study might be challenging. 
 
Along with licensing of HPV vaccination in the Western world, two concerns were 
raised around potential negative effects of vaccine receipt. In the US, it was speculated 
from conservative groups that HPV vaccination could lead to sexual disinhibition due 
to a perceived implicit approval to be sexually active, and these groups strongly 
opposed a mandated vaccination (175). This is a notion which may appear irrational 
and antiquated. Nevertheless, some media held up this concern and HPV vaccination 
was, among other things, described as “yet another green light on the road to 
promiscuity” (115). Therefore, although controversial, research is needed on this issue 
and an item on sexual behavior after vaccination was included in our survey, along with 
questions on sexual habits. We found that few respondents thought their safe sexual 
behavior could change, but that some did and more expressed uncertainty. We simply 
interpret this to signify that careful information on what protection HPV vaccination 
can, and cannot, confer should be a feature of vaccination campaigns. 
 
Some studies have shown that girls think that they themselves would not change 
behavior, but that other girls might (176, 177). Perhaps it is easier in a survey to reason 
about the altered behavior of others, rather than state that oneself could pursue less safe 
sex, for example. However, reassuring data have now emerged on this issue. A recent 
study on managed care organizational data showed little difference in adverse outcomes 
of sexual activity (defined as pregnancy/STI-testing or diagnosis; or contraceptive 
counseling) between those who received HPV vaccine and those who did not (178). 
Furthermore, a recent study in Australia showed that HPV vaccinated university 
students held more positive attitudes toward safe sexual behavior than non-vaccinated 
peers (179), and an English study among school girls shows that neither being offered 
the HPV vaccine nor receiving it affected sexual behavior (180). Thus, data in uptake 
studies are positive, although if boys/men were to be vaccinated, similar uptake 
research would be called for. 
 
The second concern on HPV vaccination is that vaccinated females might perceive 
themselves as fully protected against cervical cancer, and thus participate less in 
screening. In adult women, this would be highly risky, and even in school girls, 
continued screening participation will be key to proper evaluation of vaccine effects in 
the nearest future. In our study, we found that the youngest women were unsure of 
whether they needed as many pap smears as previously after vaccination. Again, 
researching this issue is called for and here, recent findings appear somewhat 
conflicting.  
 
In Australia, one of the first countries to implement large-scale vaccination, it was 
found in a qualitative study that the majority of girls aged 12-16 believed they were 
indeed fully protected against cervical cancer after vaccination (181), and a quantitative 
study on women age 18-27 found that 19% viewed screening as being of low 
importance following vaccination (182).   
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A study on university students found that knowledge of cervical screening guidelines 
was generally poor but that intentions to undergo screening or uptake of screening did 
not differ between vaccinated and unvaccinated women (179). An Australian study on 
women age 18-28 found that among women aware of the vaccine, 96% knew that Pap 
tests were still needed after HPV vaccination, yet 20% thought that vaccination could 
prevent all cervical cancer – which raises the question whether there might be a 
disconnect between knowing the need to participate in screening, and truly 
understanding what screening is for (183). A similar lack of understanding of what 
cervical screening meant was recently shown among young HPV-vaccinated Swedish 
women (165). 
 
In contrast to all this, a recent study from Canada showed that HPV-vaccinated women 
actually participated more in cervical screening than matched unvaccinated women 
(184). If they did, this would of course be advantageous compared to the alternative, 
that they would participate less. However, it would not be preferable from a health-
economical perspective as it would mean that we doubly protect some women, whereas 
others are doubly cut-off from both screening and vaccination. This may be of growing 
concern in the field (185). Clearly, although cervical screening has been phenomenally 
successful in reducing cervical cancer burden in industrialized countries, perceptions 
and understanding of, as well as attendance to, these programs is key to safeguard. 
Regardless of vaccination status, all women will benefit from collective efforts to 
maintain high fidelity to screening programs. 
 
6.4.4 Implications for continued research and practice 
Returning to the Swedish situation, it appears that, despite high acceptability and media 
exposure, uptake of HPV vaccination in women above 18 has been very low, and 
virtually non-existent in males. This is likely due to a combination of reasons such as 
cost, practicalities and peer behavior. Even in the subsidized age groups, where the 
state has accepted a substantial part of the cost for the vaccine, so far only around 30% 
of eligible girls have vaccinated (100). School-based vaccination of girls and young 
women appears as the most realistic way forward for ensuring reasonably high to high 
coverage of HPV vaccination, especially in risk groups. Had the catch-up program been 
organized at a high-school level, instead of entirely opportunistic; potentially coverage 
could have been much increased. However HPV vaccination continues, as stated above, 
uptake research will be essential to monitor the degree of socioeconomic equality. 
 
In contrast to the correlation between acceptability and self-perceived risk of STI, as 
described above, the acceptability of vaccination was low among respondents who had 
not yet made their sexual debut. The questionnaire information specified that HPV was 
an STI, but the benefit of vaccinating before sexual debut was clearly not obvious to all 
respondents. Perhaps virgin respondents felt that the vaccine was not intended for them, 
although it is prophylactic like all other vaccines and thus most effective if given before 
any exposure. In line with this, most respondents chose age 15-17 for age to commence 
HPV vaccination, which may indicate that understanding of general optimization of 
vaccination could be somewhat better, since in this age group, many will have made 
their sexual debut.  
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Now that school vaccination is a fact, much of the HPV vaccination benefit will be 
maximized in school children, and the Stockholm County Council advertising 
campaign website prominently mentions higher protection if vaccinated early on their 
portal page (168). 
 
Should young adults really get vaccinated after sexual debut? This is clearly a complex 
issue. Efficacy trials indicate that young adults can have a substantial protective effect 
of vaccination up until age 26, yet some effectiveness studies do not (100). The 
limitation of the randomized trials is that participants had to meet certain criteria, which 
may limit generalizability of the findings. On the other hand, in real life an older group 
with high risk for, or even prevalent, condyloma may have vaccinated first, limiting the 
generalizability of those findings to those of the same age but lower exposure to HPV.  
 
Age at vaccination is a proxy for risk of exposure to HPV: if a person has not had any 
HPV-related disease, and few sexual partners, protection should still be good even if 
she/he is around 25 years old. However, if a person of the same age has had many 
sexual partners, and perhaps even condyloma or cervical lesions, vaccine effectiveness 
will be reduced and the cost-effectiveness of vaccination both for the individual and 
society will be reduced likewise. It has now been decided that all women until age 26 
will be offered subsidized vaccination, and in Stockholm, free such. Ultimately, if the 
now extended vaccine campaigns translate into high population-level coverage up until 
age 26, future studies will be able to assess real-life effectiveness even better, which 
may yield clearer answers than we have today. 
 
The only main concern in this survey was that of vaccine safety. This was in 2007, long 
before an association between vaccination against pandemic H1N1-flu and narcolepsy 
was published (186). The association with narcolepsy garnered widespread attention in 
Swedish society (187), and now more than ever, it is of key significance to maintain 
public confidence in vaccination. In a recent report on national television, the fear of 
adverse effects such as narcolepsy was cited by young women as a contributing reason 
on why they and fewer than expected eligible girls had vaccinated against HPV. 
Reassuring safety data on HPV vaccination from Sweden and Denmark have already 
been produced (188) but clearly, to maintain public confidence in vaccination programs 
this is a key area of priority for future research and follow-up (189). Active continued 






Study I and II: 
 
- Persistent infection with HPV16 is strongly linked to the risk for both in situ 
and invasive squamous cell carcinoma.  
- The cancer risk conferred by HPV16 increases over time, whereas the risk 
conferred by HPV18 is more stable over time. 
- Non-16/18 high-risk HPV types increase the risk for both in situ and invasive 
squamous cell carcinoma, although their relative contribution is greater to 
carcinoma in situ.  
- HPV16 viral load was initially unexpectedly low in invasive squamous 
cervical cancer. However, in both in situ and invasive squamous cell 
carcinoma, HPV16 viral load increases quickly in the last few years before 
diagnosis.  
- HPV16 viral load is linked to future risk for both in situ and invasive 
squamous cell carcinoma, but the risk functions are complex and differ over 
time. 
- Hence, HPV16 viral load may struggle to improve HPV-based screening but 
may carry important implications when weighing sensitivity against 
specificity in such screening. 
Study III and IV: 
 
- Pre-large scale vaccination campaigns; awareness of condyloma and cervical 
cancer was high in the young adult and adult Swedish population, but 
awareness of HPV and the causal relationship to these diseases was low. 
- The understanding that men could contract HPV was deficient, and 
information campaigns for vaccination should correct this, especially if male 
vaccination is ever to become an avenue for infectious disease prevention. 
- Hypothetical acceptability of HPV vaccination was quite high among young 
adults in Sweden pre-large scale vaccination campaigns, although until today, 
only few have gotten vaccinated. Information on the benefit of early 
vaccination is needed.  
- Future research should concentrate on actual vaccine uptake, and vaccine 
safety. 
- Few young adults stated their healthcare-related behavior would change after 
vaccination, which is reassuring. Correct information on the benefits and 
limitations of HPV vaccination should be given when vaccinating this group. 
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8 SUGGESTIONS FOR FUTURE RESEARCH 
 
The means to prevent cervical cancer have now been made available in the form of 
testing and vaccinating against HPV, and the scientific and clinical communities have 
an opportunity to remove such a large part of the disease that it might be possible to 
speak of eradication. Yet these tools are far from fully implemented. Thus, although 
revolutionary cancer vaccines have been developed, several public health challenges 
remain in order to achieve optimal cancer control. These are some general suggestions 
for future research and practice. 
 
• Design of, and attendance to cervical screening 
Of significance in cervical screening, the gap between science and practice should not 
be allowed to widen too far or too quickly. Several countries, even some highly 
developed European such, still today lack high-quality nation-wide organized cervical 
cytological screening programs, or only recently introduced such. In this context, HPV-
based screening may present a fresh start, but can also require large-scale investment in 
countries which just recently managed to organize cytological screening.  
Strategies to increase participation to screening would likely be successful in 
decreasing cervical cancer incidence in Sweden, whether this screening is cytological 
or HPV-based. Options to increase participation to screening might want to move 
beyond traditional reminders of attending. Similarly to mobile blood donations, a 
mobile cervical screening unit was introduced in parts of Sweden in 2010. Also, self-
sampling for HPV in the home might be a future avenue for organized screening, 
although the women diagnosed with HR-HPV will still have to come in for further 
testing and the acceptability of self-sampling may differ between different groups.  
 
In the future, the HPV-based screening scenario will present several specific logistical 
challenges. Since a negative HPV test confers longer protection test compared to a 
negative cytological smear, screening intervals will be lengthened and differ depending 
on HPV status. This will place high demands on screening organization and recall-
systems. It might be a future challenge to bring women in to screening again after ten 
years, especially as some data indicate that women consistently underestimate the time 
since their last cervical screen.  
 
• Acceptability and consequences of HPV-based screening 
Whereas HPV-based screening conceptually speaking is logical, on the verge of 
elegant, in real life successful implementation relies on a number of factors. A new 
intervention is about to be presented into the female population, and research indicates 
that psychosocial effects could be seen. Of crucial importance, therefore, is to examine 
women’s acceptability of HPV-based screening, and how well-equipped the clinical 
staff doing the follow-up is to handle women with positive results. For example, when 
HPV-based screening is introduced, some women might not be satisfied with being 
declared HPV+ but cytologically negative, and thus not in need of screening for 
another three years (according to proposed guidelines).  
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It will be of great interest to follow whether such women instead get more opportunistic 
cytological smears, or HPV testing, as a result. 
 
• Uptake of HPV vaccination 
As described, uptake in organized vaccination programs has varied so far. Programs in 
Australia and the UK have succeeded, while the Dutch program failed with to reach 
more than 56%. It is crucial to study those that do not accept vaccination for their 
children, although such research might likely be difficult. In Sweden, large social 
disparities in who participates in the catch-up program have been identified and need to 




Perhaps the greatest challenge in the coming years will be to clarify that cervical cancer 
prevention, at the end of the day, really is infectious disease prevention (190). At first, 
it was believed that HPV vaccination would be extremely expensive. The vaccine’s 
preventive effect on cervical cancer, rather than the agent HPV, was therefore the 
natural focus of campaigns to introduce and subsidize the vaccine. With public tenders 
and two vaccine manufacturers in competition, however, the actual price obtained has 
been greatly reduced. This could mean a drastically changed cost-effectiveness ratio 
for, e.g., male vaccination. I would here like to state that it is my personal opinion that 
males should be vaccinated against HPV, since this would likely achieve the benefit of 
a quicker removal of HPV and related diseases from the population. However, the 
debate on whether to aim for eradication, or settle for herd immunity in men from 
female vaccination, is ongoing and likely needs to be informed by further trials before 
public health policy will be altered. 
 
Further, the HPV vaccination field appears to be in a state of scientific flux: “truths” 
that previously were apparent become outdated in only a few years’ time. Initially, it 
was believed that there would be limited, if any, cross-protection against non-vaccine 
types. An expanded vaccine was therefore actively called for (by among others, 
ourselves in Study I). Today these voices have somewhat diminished. The cross-
protective effect in vaccine trials has surpassed expectations. Thus, the additional 
benefit might be less clear. Head-to-head trials on an expanded, versus the existing, 
vaccine should illuminate the issue, yet have not reported any results so far. Moreover, 
the effect on population level was thought to take some time to achieve, especially if 
only vaccinating girls, yet Australian data already show a drastic drop in HPV 
prevalence, and partial herd immunity. A chief future issue might not be the number of 
types included in the vaccine after all, but to reach a high population-level of coverage, 
and to reach the highest risk groups for cervical cancer, and other HPV-related cancer.  
 
Although many obstacles remain, the potential to greatly reduce HPV-related morbidity 
and mortality appears within reach, and it will be the challenge for public health policy 
to see this potential realized. If successful, cervical cancer may come to serve as a 
model system for state-of-the-art disease prevention. 
 
Karin Sundström, Stockholm, December 2012. 
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